

Third N-ECCO Consensus Statements on the Nursing Roles in Caring for Patients with Inflammatory Bowel Disease

Susanna Jäghult^{*1,} , Michel Adamina^{2,} , Dawn Farrell³, Palle Bager^{4,} ,
Wladyslawa Czuber-Dochan^{5,} , Karen Kemp⁶, Nynke Boontje⁷, Ferdinando D'Amico^{8,} ,
Goedele Dewitte⁹, Ola Haj¹⁰, Petra Hartmann¹¹, Daniel Lightowler^{12,13}, Regula Locher¹⁴,
Clarisse Maia¹⁵, Francisca Murciano Gonzalo¹⁶, Daniele Napolitano^{17,} ,
Berna Nilgün Özgürsoy Uran¹⁸, Katarina Pihl Lesnovska¹⁹, Shellie Radford^{20,} ,
Adriana Rivera Sequeiros²¹, Chen Sarbagili-Shabat^{22,} , Tanja Tiitta Inkeri Toivonen²³,
Catherine Walsh²⁴, Debora Zaetta²⁵, Simona Radice²⁶

¹Department of Clinical Science and Education, Karolinska Institute, Södersjukhuset, Stockholm, Sweden

²Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

³Department of Nursing and Healthcare Sciences, Munster Technological University, Tralee, Co. Kerry, Ireland

⁴Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark

⁵Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, London, United Kingdom

⁶Department of Gastroenterology, Manchester Royal Infirmary, Manchester, United Kingdom

⁷Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands

⁸Department of Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital, Milan, Italy

⁹Gastroenterology, UZ Gent, Ghent, Belgium

¹⁰Gastroenterology Department, Sheba Medical Center, Ramat Gan, Israel

¹¹Gastroenterologische Gemeinschaftspraxis Minden, Minden, Germany

¹²AW Morrow Gastroenterology & Liver Centre, Royal Prince Alfred Hospital, Sydney, NSW, Australia

¹³Medical School, University of Western Australia, Crawley, WA, Australia

¹⁴Gastroenterology/Hepatology Department, Clarunis Universitäres Bauchzentrum Basel, Basel, Switzerland

¹⁵ULS São João, Porto, Portugal

¹⁶Gastroenterology Department, Hospital del Mar, Barcelona, Spain

¹⁷Centro di Malattie dell'Apparato Digerente (CEMAD), Fondazione Policlinico Gemelli IRCCS, Rome, Italy

¹⁸Health Science Faculty, Izmir Katip Celebi Universitesi, Izmir, Turkey

¹⁹Department of Gastroenterology & Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden

²⁰School of Medicine, NIHR Nottingham Biomedical Research Centre, Nottingham, United Kingdom

²¹Nursing Research Unit, Virgen Macarena University Hospital, University of Seville, Seville, Spain

²²Department of Paediatric Gastroenterology and Nutrition, Amsterdam University Medical Centers, Emma Children's Hospital, Amsterdam, The Netherlands

²³IBD Centre, Tampere University Hospital, Pirkanmaa Wellbeing Services County, Pirkanmaa, Finland

²⁴Letterkenny University Hospital, Letterkenny, Ireland

²⁵Gastrointestinal Inflammatory Disease Departmental Unit, Department of Surgery, S. Maria del Prato Hospital, Feltre, Italy

²⁶IBD Center, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Milan, Italy

*Corresponding author: Susanna Jäghult, Department of Clinical Science and Education, Karolinska Institute, Södersjukhuset, Sjukhusbacken 10, SE-182 83, Sweden (susanna.jaghult@gmail.com).

Key words: IBD nurse; nursing role; IBD.

Introduction

The Nurses Committee of the European Crohn's and Colitis Organisation (N-ECCO) is an active Committee of the ECCO that aims to improve access to nurse education in inflammatory bowel disease (IBD) throughout Europe and to provide a link with national nursing networking organizations. The first N-ECCO Consensus Statements were published in 2013 and

sought to identify the positioning of nurses in the care of patients with IBD and to provide a consensus on the ideal standard of minimum care that patients with IBD might expect. The first update was made in 2018. The N-ECCO Consensus Statements have been widely distributed internationally, guiding IBD centers and IBD nurses to establish the most optimal quality of care in IBD. High-quality IBD care requires working

within a multidisciplinary team (MDT). Core team members should include at least one IBD nurse, a gastroenterologist, a colorectal surgeon, a radiologist, and a dietitian. In this MDT, the IBD nurse has a clear role as coordinator between the patient and the different disciplines, with the objective of providing a holistic approach to care.^{1,2} In addition to administering and monitoring treatments, IBD nurses provide education, support, counselling, and advocacy for patients. Even if the role of the IBD nurse has become more established in recent years, several differences between countries remain, including variations in education and role. In the two previous N-ECCO Consensus Statements, the statements were divided into fundamental and advanced IBD nursing. Due to the different conditions across countries, this division was removed in this update.

The overall aim of ECCO is to improve the care of patients with IBD through development of guidelines, education, and research. The N-ECCO Consensus Statements seek to realize this aim from an IBD nursing perspective, by providing statements and evidence to guide and ensure the ideal standard of care.^{3,4} This third update aims to provide a framework for IBD nurses to continue delivering high-quality and evidence-based care, to consider the needs of diverse patient populations, and to include new technical tools.

Method

Two project coordinators, SR and SJ, were first selected by the N-ECCO Committee. A panel of 23 participants was then chosen from an open call, resulting in a total of 25 experts. The criteria for participant selection were primarily based on academic expertise. Other factors were also considered, such as gender balance and geographic distribution. In addition to IBD nurses, the panel also included two gastroenterologists and one dietitian. The participants were split into four working groups (WG), with one leader for each WG. Two patient representatives, selected by The International Federation of Crohn's and Ulcerative Colitis Associations, were also involved in voting and reviewing the statements. The panelists were also supported by professional librarians.

Topics were decided by the project coordinators and the WG leaders partly according to the results of a survey distributed to all N-ECCO members. The topics were then divided between the four WGs. For each topic, a research question was formulated using the Population, Intervention, Comparison, Outcome (PICO) method. The professional librarians performed literature searches on the platforms Cochrane Library, PubMed, Medline, Embase, CINAHL, PsycINFO, Scopus, and Web of Science. A search algorithm was developed where the aim was to include recent, high-quality studies, which meant that the search first focused on meta-analyses, systematic reviews, or randomized controlled trials (RCT) from 2017 onwards. If no eligible studies were identified, other experimental research could be reviewed. The identified and relevant articles were first screened for titles and abstracts by two participants for each research question. For the identified and relevant articles, full-text screenings were performed by one participant. A first draft of statements with supportive text was then developed. The statements follow the Oxford Levels of Evidence, where EL1 is the strongest evidence and EL5 the weakest (<https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebml-levels-of-evidence>). All statements underwent two rounds of online voting. At the first voting round, the panelists participated and revisions were made afterwards. At the second online voting, N-ECCO national

representatives and the two patient representatives also participated. For both voting rounds, an agreement of 80% or more of the participants was defined as consensus. Additional revisions were made by the WGs after the second online voting. The panelists and patient representatives then met at a face-to-face meeting to discuss and vote on the final version of all statements. The final version of all 20 statements was reviewed and approved by the ECCO Governing Board.

Statement 1. Health care institutions are recommended to establish and support specialist IBD nurse roles within MDTs. Specialist IBD nurses are associated with reduced IBD-related hospitalizations, readmissions, emergency admissions as well as improved patient satisfaction and cost-effectiveness [EL3]

Inflammatory bowel disease nurses play a key role within the MDT, and integrated nurse-led practice is now a well-established care model in IBD.⁵⁻⁷ Multiple studies demonstrate that IBD nurse involvement is associated with reduced IBD-related hospitalizations, emergency department presentations, and outpatient visits.⁷⁻¹⁴ The important contribution of IBD nurses to improved patient outcomes has been confirmed by two systematic reviews, although it should be noted that many included studies are limited by observational, single-center designs and varied methods.^{5,6} Cost-effectiveness has been consistently reported, with several studies showing substantial savings at the organisational level¹²⁻¹⁴; one Australian study estimated an annual net savings of \$570,838 AUD.¹²

Alongside these economic benefits, involvement of IBD nurses in care delivery improves patient satisfaction and quality of life (QoL).¹⁵⁻¹⁷ In a nationwide audit from the U.K., patients reported improved care and valued access to specialist nurses.¹⁶ A RCT from Germany revealed improvements in QoL among patients with lower baseline QoL scores.¹⁸ Irritable bowel disease nurse-led services also improve clinical efficiency. For example, introduction of a nurse helpline and virtual clinic in Australia significantly reduced outpatient clinic use.⁹ Irritable bowel disease nurse remote monitoring can contribute to overall health service efficiency and cost reduction.¹⁹

Evidence for the role of IBD nurses in supporting medication adherence is limited. One retrospective cohort study revealed reduced health care costs and improvements in adherence and persistence among patients using biological therapies who accessed a home health nurse program.¹⁰ A second study, based on patient surveys, suggested a demand for nurse-led medication education.²⁰ These findings highlight the potential role of IBD nurses in medication education and support, but further research is warranted.

Statement 2. Inflammatory bowel disease nurses are recommended to be active members of the MDT and provide structured interventions, such as education, care coordination, psychosocial support, and facilitation of investigations and treatment adjustments to patients with IBD [EL3]

Patients with IBD often face multiple challenges that are related to disease activity and living with a chronic condition. These challenges are optimally addressed within MDTs. Such collaborative care improves patient-reported outcomes, reduces symptom burden, enhances treatment adherence, lowers

hospitalization rates, and increases overall patient satisfaction.^{6,8,12,18,21,22} Care delivered by MDTs and guided by clinical guidelines or consensus statements is recommended based on evidence from systematic reviews.^{5,18,19}

As defined by N-ECCO and the UK consensus standards,^{4,23} the IBD nurse occupies a pivotal role within the MDT, moving beyond standard care to act as the lead liaison for patients and clinicians alike. Their responsibilities range from care coordination and facilitation of investigations to psychosocial support, ensuring that the MDT functions cohesively. This central position allows the nurse to integrate the expertise of core members (such as gastroenterologists, surgeons, dietitians, radiologists, pathologists) and ancillary specialists (including pharmacists and oncologists) into a unified patient management plan.⁶

Recent evidence supports this role. A RCT compared additional care from an IBD nurse specialist with standard care. The study, which included 1086 patients with IBD, found no overall difference in disease-specific QoL at 6, 12, or 18 months. However, patients with impaired QoL at baseline did show significant improvement following the intervention.¹⁸

The IBD nurse contributes to efficacy of management and facilitates the delivery of high-quality care.^{8,12} Single-center studies revealed reductions in unscheduled visits, enhanced self-care, and improved QoL and satisfaction with MDT-led interventions.^{8,12,21,22}

Statement 3. Inflammatory bowel disease nurses should recognize and support effective psychological interventions to reduce distress, incorporate psychological screening, and refer patients to appropriate services [EL3]

Inflammatory bowel disease is associated with a significant psychological burden, including anxiety, depression, stress, and impaired health-related quality of life (HRQoL). Evidence consistently highlights a significant gap in psychological support for people with IBD, despite clear associations between psychological distress and poorer clinical outcomes, including increased emergency department visits and higher health care costs.²⁴

Multiple RCTs have demonstrated the effectiveness of psychosocial interventions, such as cognitive behavioral therapy (CBT), acceptance and commitment therapy (ACT), mindfulness-based programs, and psychoeducation.^{25–37} These interventions reduce anxiety, depression, disease-related worries,^{28,33,38} and stress^{28,38} to improve coping, HRQoL,²⁵ and overall well-being. Some interventions produced short-term improvements in mental QoL,³⁹ while others provided benefits in disease-specific concerns and psychological resilience. The value of integrating psychological care into IBD management is supported by research findings, regardless of whether the interventions were delivered as 1-day workshops or ongoing group sessions.⁴⁰

Structured patient education and peer-support programs, particularly for adolescents and young adults,³⁹ also improve psychosocial outcomes and foster adaptive coping.⁴⁰ Qualitative evidence from CBT- and ACT-based studies suggests that psychoeducation can improve emotional adjustment and illness acceptance.^{27,38}

Incorporating screening tools into routine assessments and facilitating access to psychological services are key areas where IBD nurses are well positioned to help, despite the relative scarcity of reports on nurse-led psychological interventions.

With appropriate training, nurses could contribute to the delivery of structured psychoeducational and peer-support programs as part of a MDT. Integrating psychological screening and referral pathways into IBD management is recommended as a strategy to improve patient health and reduce the burden on health care resources.

Statement 4. Inflammatory bowel disease nurses should offer a structured support program for patients with IBD on advanced therapies, as this will improve disease management and medication adherence and assist with safety issues [EL3]

Nurses are central members of the IBD MDT, having an important role in patient education on disease course, treatment options, safety, and adherence.⁴¹ Through nurse-led patient-centred support programs utilizing structured communication strategies, patients can become more confident and adherent to their advanced therapy, which can lead to overall reductions in health care expenditures by 10%–20%.^{12,42–48} Structured communication strategies may include communication frameworks, question prompt lists, frameworks for shared decision making, use of tailored language, and visual aids.

A large study has shown that patient-support programs based on person-centred strategies improve outcomes for patients with autoimmune diseases by helping them better understand their therapies and manage a complex treatment regimen.⁴⁹ This should encompass a patient-centred approach toward the decision-making process that considers the decision-making preferences of the patient.⁵⁰

The responsibilities of the nurse within the MDT have great importance, as the nurse is more regularly in contact with the patient, undertakes safety and drug monitoring, and is the first person the patient contacts with concerns or for further advice.^{18,51,52}

Nurse-led telemonitoring, through telephone and web-based mechanisms, is as effective as usual care in achieving and maintaining short-term remission, while also improving adherence and clinical outcomes.^{47,53–55} Proactive therapeutic drug monitoring (TDM) undertaken by nurses leads to similar clinical outcomes as those seen in reactive TDM after 1 year of follow up.⁵⁶ Therefore, nurse-led TDM strategies should be tailored to the patient and the drug being administered.⁵⁷

Patients have increased interest in educational topics, such as diet and nutrition and specific education around treatment with biologics.⁵⁵ Research has suggested significant patient benefit in outcomes and QoL from an IBD nurse who provides structured sessions, which improve injection device knowledge, provide demonstration-device practice, and focus on both emotional and practical aspects of living with IBD. These structured sessions increase patient confidence, reduce burden on IBD nurses and the wider health care team, and improve probability of success of advanced therapy.^{18,58–60}

Statement 5. Inflammatory bowel disease nurses should support and participate in an early, structured, and collaborative transition program for adolescences with IBD [EL3]

Although structured transition programs for adolescents with IBD are associated with improved clinical and patient-reported outcomes, there remains considerable variability in

implementation across centers, and no standardized model currently exists.⁶¹ Multiple systematic reviews and studies highlight the positive impact of transition clinics and structured interventions, including improved adherence, disease knowledge, self-efficacy, clinic attendance, and reductions in hospitalizations, emergency department visits, flares, and surgery.^{62–65} A key component across successful models is the presence of a transition coordinator, who may be an IBD nurse who fulfills a role encompassing care planning, readiness assessment, education, and continuity of care.^{61,62,65–67} Nurse-led coordination supports multidisciplinary collaboration, facilitates patient and family engagement, and ensures progress through individualized, age-appropriate milestones. The key to optimizing outcomes for adolescents with IBD may lie in the consistent presence of trained IBD nurse specialists acting as transition coordinators. While financial and organizational challenges currently hinder care,⁶⁷ systemic policy support should be directed toward empowering nurses to lead collaborative transition processes. Formalizing the nurse's role within future guidelines is the most effective way to address current barriers and deliver the standardized, integrated care these patients require.

Statement 6. Inflammatory bowel disease nurses should assess health risks and frailty in older patients with IBD and balance disease severity, comorbidity, and patient expectations [EL5]

The prevalence of IBD is increasing globally. An estimated 30% of patients with IBD worldwide are aged >60 years.^{68–72} Older adults (definition of older adults by age on the United Nations' criteria: individuals aged 60 years or above) with IBD can be categorized into the following two groups: “non-elderly onset” (who later transition to old age) and “late-onset” (disease onset at age ≥60 years). Inflammatory bowel disease nurses should be aware of the distinction between these two groups, as they may have different epidemiology, phenotypes, and outcomes.^{70,71}

Although the goals of care for older adults with IBD are similar to those of younger age groups, management of IBD in the older person differs.^{73,74} Inflammatory bowel disease care in the older person requires special considerations on frailty and specific disease characteristics rather than chronologic age.^{69,70,72,75} Symptom control is paramount, as older patients will often choose a better QoL and are less concerned about the risks of long-term complications.⁷⁶ A comprehensive IBD nursing assessment should be balanced between disease severity, comorbidity, risk and benefits, life expectancy, and patient preferences. Nursing care must involve an understanding of not only treatments but also management of increased disposition to infections, risk of fracture, physical and nutritional frailty, incontinence, sensory loss, disturbed sleep, cognitive deficit, depression, and malignancy.⁷⁷ In the case of rectal therapies, incontinence, limited mobility, or impaired coordination skills deserve consideration.⁷⁶ Polypharmacy can also significantly interfere with the management and course of IBD.^{72,78} This may influence health care costs, burden on caregivers and patients, and medication non-adherence.⁷⁷ As older patients are particularly vulnerable, nursing care should also focus on factors beyond mitigation of disease activity. Factors such as restricted mobility, depression, widowed status, and reduction of functional independence may contribute to a lower perceived physical HRQoL and social isolation.⁶⁸

Multiple coexisting chronic diseases may warrant co-management with a geriatrician to integrate complex care and geriatric assessment as a reflection of the patient's health, including the somatic (comorbidity, polypharmacy, malnutrition), functional (daily living, physical capacity), social (support system, well-being), and mental (depressive symptoms, cognitive impairment) domains.^{69,75,79–81} After the age of 65 years, 17% of patients have a cognitive decline that often further complicates the diagnosis and management of IBD.^{70,75,76,80} Inflammatory bowel disease nurses may support caregivers through training and education and work closely with social workers, geriatricians, and mental-health professionals to promote a person-centred approach. Unavailability or lack of reliable interactions with technology may hinder access to certain care services.^{74,82} Whenever possible, in-person interactions are preferred over virtual methods.^{80,82}

Statement 7. Inflammatory bowel disease nurses should recognize the importance of dietary strategies in managing patients with IBD and provide optimal and individualized dietary support [EL5]

Inflammatory bowel disease nurses play a pivotal role in patient education, early identification of nutritional concerns, and timely referral to dietitians. By measuring anthropometric parameters, using malnutrition risk-screening tools (e.g., Malnutrition Universal Screening Tool), routine monitoring of micronutrient status and hydration, and detecting nutritional deficiencies, nurses can identify patients who need further nutritional assessment. A multicenter pilot study showed that a structured nursing-led intervention combining assessment, individualized advice, referral to a dietitian, education, and follow up was feasible and significantly improved nutritional status.⁸³ Dietary education and support may also reduce the risk of complications. In patients requiring surgery, poor nutritional status increases the risk of postoperative complications, while preoperative nutritional support, particularly enteral nutrition (EN), can reduce this risk.^{84,85}

To provide optimal and individualized dietary support, nurses should recognize the different dietary strategies as therapeutic tools in IBD.⁸⁶ The best-established dietary treatment for active Crohn's disease (CD) is exclusive enteral nutrition (EEN), which can induce clinical remission at rates comparable with corticosteroids in adult patients with CD.^{87,88} However, there is insufficient evidence to support the use of EEN as an adjunctive therapy in active ulcerative colitis (UC).⁸⁹ Exclusive enteral nutrition is more effective than partial enteral nutrition (PEN) as induction therapy for CD.⁹⁰ However, when PEN is combined with the Crohn's Disease Exclusion Diet, its efficacy appears comparable to EEN. Crohn's Disease Exclusion Diet + PEN is a viable alternative for mild-to-moderate active CD.^{90–95} Limited evidence supports the Mediterranean diet⁹⁶ and the Specific Carbohydrate Diet⁹⁷ in CD. In UC, the UC exclusion diet and 4 strategies to Sulfide-REduction diet^{98,99} have shown promising results in inducing remission, although further studies are needed before formal recommendation.

Partial enteral nutrition is effective in patients with CD for maintaining remission.^{90,100,101} Limited evidence suggests improved disease outcomes with reduced intake of red meat in UC,^{102,103} reduced intake of ultra-processed foods in CD,¹⁰⁴ and

adherence to a Mediterranean diet.^{105,106} For patients with IBD in remission who experience irritable bowel syndrome (IBS)-like symptoms, the low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet is recommended.^{107,108}

Nutritional assessment and management should be performed by an IBD-specialized dietitian. Due to their nutritional and psychosocial risks, referral is strongly recommended particularly when restrictive diets are used. Where IBD-specialized dietitian expertise is unavailable, health care professionals with appropriate nutrition training may provide support.⁸⁶

Statement 8. Inflammatory bowel disease nurses may play a proactive role in structured pretravel counselling for patients with IBD, including vaccination advice and treatment continuity [EL5]

Travel abroad is frequent among patients with IBD but remains clinically challenging. Between 21%-46% of patients experience diarrhea or a disease flare during or after travel, and 4%-9% require hospitalization abroad.^{109,110} An international cohort of 1878 patients with IBD revealed that 28% experienced travel-associated exacerbations and up to 30% reported difficulties transporting or storing biologics during travel, particularly maintaining the cold chain.¹¹¹ High-altitude travel is also relevant, with 46% of patients reporting a flare during or after visiting destinations that require such travel.¹¹⁰⁻¹¹² Anxiety and uncertainty are common, as 61% of patients report travel-related health concerns and many travel during or shortly after a flare.^{110,113}

Survey data reveal significant unmet needs in pretravel care that are directly relevant to nursing practice, even though interventional studies specifically assessing nurse-led counselling in IBD are currently lacking. In two outpatient cohorts, only 23% of patients actively sought pretravel medical advice despite 70%-78% reporting in the survey an interest in structured guidance.^{109,110} Similarly, international studies of health care professionals, mainly nurses, revealed that only about half felt confident providing such guidance, particularly on vaccination and destination-specific risks.^{109,113} These findings indicate behavioral and informational barriers for patients and providers. Preventive care is also incomplete, with 42%-48% of patients reporting that they did not receive vaccination advice before travel and up to 12% received live vaccines despite immunosuppression.^{111,112,114} In addition, 32%-60% of patients travel without appropriate insurance.^{110,111}

These gaps define clear areas for IBD nurses to provide structured guidance and coordinate pretravel preparation in collaboration with other health care professionals, including reviewing immunization status and contraindications; providing tailored vaccine education; advising on cold-chain maintenance and medication transport; documenting medications; addressing psychosocial concerns and red-flag symptoms; and offering hydration strategies for acute diarrheal episodes using salt-sugar or oral-rehydration solutions.¹⁰⁹⁻¹¹³ Digital-health resources may serve as valuable adjuncts to clinical care by offering supplementary support for patients during travel.^{109-111,113}

Statement 9. Inflammatory bowel disease nurses should provide structured pre- and postoperative education and support for patients with IBD to improve self-efficacy, decrease psychological distress, and enhance QoL and satisfaction with surgical care [EL3]

Surgical intervention is a pivotal concern for many patients with IBD. Comprehensive, structured educational and support programs coordinated by IBD nurses and delivered in collaboration with the MDT should be considered best practice in surgical IBD care. The perioperative period is often marked by heightened anxiety, unmet informational needs, and risk of complications. Evidence supports the implementation of structured educational and supportive programs, including preoperative information on surgical procedures, recovery expectations, ostomy care (when applicable), and emotional support.¹¹⁵⁻¹¹⁹ Structured education and decision aids improve patient preparedness, reduce decisional conflict, and foster shared decision making.¹¹⁵⁻¹¹⁷ Participatory approaches that incorporate patient feedback are particularly important to ensure informed consent and to align surgical choices with the patient's values.^{115,119}

Preoperative counselling tailored to risk factors, such as obesity, immunosuppressive therapy, and disease severity, improves both perioperative safety and long-term outcomes.¹²⁰⁻¹²⁴ Nutritional optimization as a part of prehabilitation may reduce surgical stress and shorten recovery times.¹²⁵ Postoperatively, structured follow up with individualized information and coordinated-care pathways reduced readmission rates and improved patient-reported outcomes.¹²⁶⁻¹²⁸

For patients with IBD undergoing stoma surgery, pre- and postoperative education is central to promoting self-management, preventing complications, and enhancing QoL.¹²⁸⁻¹³⁰ Delivery of such care benefits from an interdisciplinary approach, with contributions from stoma care nurses, surgeons, dietitians, psychologists, and IBD nurses.¹³¹⁻¹³³ Special considerations are also needed for pregnant or pediatric populations due to hernia risk and body image concerns.^{133,134} Tailored, patient-centred programs that integrate surgical expectations, ostomy education, and psychosocial support have consistently improved coping, mental health, and patient satisfaction.¹³⁵⁻¹³⁷

Care delivered in specialized, high-volume centers with dedicated IBD teams is associated with improved surgical outcomes and more consistent application of educational protocols.¹³⁸⁻¹⁴⁰ Standardization of these interventions within Enhanced Recovery After Surgery protocols and clinical-care pathways is recommended for both elective and urgent surgery.^{141,142}

Statement 10. Inflammatory bowel disease nurses should provide structured education and counselling to patients with IBD who experience fistulae, abscesses, or extraintestinal manifestations to improve treatment adherence, early complication recognition, symptom management, and psychosocial adjustment [EL5]

Inflammatory bowel disease patients who develop complications such as fistulae, abscesses, or extraintestinal

manifestations (EIM) often face complex care pathways and emotional challenges. The ECCO guidelines highlight the importance of clear communication, patient awareness of red-flag symptoms, and coordinated referral among specialties to ensure safety and continuity of care.¹⁴³ In perianal CD, counselling should address not only medical and surgical options but also wound or stoma care, body image, and coping strategies.^{144,145} Nurse-led follow up and empathetic communication promote adherence and reduce recurrence.^{146,147} While education alone may have limited impact on disease activity, multi-component and behaviorally focused programs improve knowledge, coping, and adherence.^{118,148,149} Structured counselling also enhances medication safety and satisfaction.¹⁵⁰ For patients facing the complexities of fistulizing disease or EIMs, IBD nurses serve as the vital link to essential care. Their role is central to meeting the high informational and emotional demands of this cohort, as they are uniquely positioned to deliver the proactive education and psychosocial support necessary to manage these challenging symptoms.^{151,152}

Statement 11. Inflammatory bowel disease nurses should provide tailored education and support to patients with IBD experiencing bowel urgency and fecal incontinence [EL3]

It is recommended that IBD nurses provide structured, individually tailored education and support to patients with IBD experiencing bowel urgency and fecal incontinence.^{153–155} This may include information on underlying mechanisms, pelvic-floor exercises, bowel retraining, dietary advice, and emotional support. Structured self-management programs should consider patient preferences and symptom profiles.^{154,155}

Bowel urgency and fecal leakage are distressing and often underreported symptoms that affect 31%–74% of patients with IBD, often irrespective of disease activity.¹⁵³ As disclosure is frequently hindered by stigma, embarrassment, and perceptions of an untreatable condition, this emphasizes the need for supportive, nurse-led dialog to normalize discussion and facilitate timely interventions.^{153,155}

Structured nurse-led education and support can improve continence outcomes, self-efficacy, and psychological well-being. Usual care typically consists of routine monitoring or general advice without structured intervention.¹⁵⁵ Tailored strategies remain essential, as no single approach benefits all patients. The IBD nurse may also provide information on diagnostic methods such as anorectal manometry or MR-defecography. Collaboration with physiotherapists or psychologists may be required for interventions such as pelvic-floor therapy, biofeedback, or psychological support.^{154,155}

Randomized controlled trials have highlighted both the promise and the challenges of self-management programs. The IBD BOOST trial evaluated a digital facilitator-supported program and revealed no significant benefit over usual care in QoL or symptom relief, although the adherence rate was low (57% completed ≥ 4 sessions).^{155,156} A trial of a self-management booklet identified barriers to participation, including reluctance to self-identify as “incontinent,” with patients preferring terms such as “urgency” or “leakage”.¹⁵⁷ Sensitive communication is therefore critical.^{153,157}

Non-invasive strategies that are effective in the general population (pelvic-floor physical therapy, biofeedback, and dietary

modulation) are increasingly supported in the context of quiescent IBD.¹⁵⁷ Both a systematic review and an expert opinion emphasized the value of simple, safe, and stepwise approaches, starting with education, bowel modifiers, and physical therapy and progressing to minimally invasive interventions when needed.^{154,158}

Nurse-delivered, multimodal continence programs show significant promise, even though IBD-specific evidence is currently limited.¹⁵⁸ Integration of psychological perspectives is also critical, as patients with IBD may benefit from understanding how cognitive and emotional responses to chronic symptoms can perpetuate distress. Framing this within the brain–gut axis may reduce stigma and promote symptom self-management.¹⁵⁹

Statement 12. Inflammatory bowel disease nurses should assess and manage pain in patients with IBD through structured counselling, supporting coping strategies, and facilitating access to effective and adjunctive therapies [EL3]

Although several studies have examined the role of IBD nurse-led care on pain management, the evidence remains inconclusive. While some findings suggest potential benefits,^{160–163} such as reduction in analgesic use, a RCT¹⁵⁶ failed to demonstrate statistically significant improvements in pain control, pain-related disability, or self-efficacy. These findings highlight the need for further prospective research with larger sample sizes and longer follow-up periods to determine the effect of IBD nurses on pain outcomes. IBD nurses may contribute to pain management through structured counselling and tailored educational interventions that help patients better understand their symptoms, identify triggers, and manage their condition. Through these interactions, nurses support individuals in developing practical coping strategies, such as relaxation techniques, pacing of daily activities, problem-solving skills, and methods to manage stress and anxiety that can reduce the perception of pain and improve overall self-management. Additionally, they can facilitate access to adjunctive therapies (e.g., acupuncture) and coordinate multidisciplinary resources, including psychological support or other appropriate services.^{15,22,164–168} A RCT confirmed a greater improvement in QoL in patients managed with IBD nurse support compared with those receiving standard care.¹⁵⁶ This effect was statistically significant in the subgroup of patients with coexisting IBS, further supporting the rationale for implementing IBD nurse-led interventions to improve patient-reported outcomes. In addition to clinical benefits, IBD nurse involvement has demonstrated cost-effectiveness, with reported health care savings of £746 per patient per year of follow up.¹⁶⁹ Although evidence for direct effects on pain remains limited, the proactive role of IBD nurses in assessment and coordination positions them to support patients experiencing chronic pain and to identify those who may benefit from specialist interventions.^{159,170} Further large studies are needed to establish the role of the IBD nurse in chronic pain management.

Statement 13. Inflammatory bowel disease nurses should assess and manage fatigue in patients with IBD through structured counselling, supporting coping strategies, and facilitating access to effective therapies [EL3]

Fatigue is one of the most common and burdensome symptoms in IBD and affects 40%-50% of patients in remission and up to 80% during active disease.^{171,172} Evidence from small RCTs, feasibility studies, and systematic reviews indicates that multi-component, patient-centred educational and counselling interventions and electroacupuncture can improve fatigue-related outcomes.^{156,173-180} Psychoeducation and CBT, including mindfulness-based approaches, consistently reduce fatigue severity and impact relative to usual care.^{173,174} Systematic reviews, including Cochrane analyses, revealed that non-pharmacological interventions, such as CBT, mindfulness-based CBT, sleep and activity guidance, and energy-conservation strategies, produced small-to-moderate improvements in fatigue and related outcomes, although sample sizes and methodologies varied.^{156,175-180} Benefits may also be sustained after mindfulness-based interventions.^{181,182} Routine fatigue screening using validated tools (e.g., the IBD-Fatigue Scale)¹⁸³ is recommended to identify and monitor symptom severity and impact and to inform targeted management.

Behavioural programs incorporating pacing, graded activity, and lifestyle modification improve perceived energy, functioning, and self-management confidence.¹⁸⁴⁻¹⁸⁶ Such interventions enhance coping strategies and fatigue-related knowledge, contributing to improved self-efficacy.^{173,174,178} Psychological benefits, including reductions in anxiety, depression, and stress, are reported consistently, alongside improvements in HRQoL.^{180,182,185,187,188} Sleep management and nutritional education are emerging components of holistic fatigue interventions. Sleep-focused strategies address a recognized mechanistic contributor to fatigue,¹⁸⁹ while nutrition screening and guidance may further support self-management and energy regulation.

These interventions are safe and well accepted, with attrition rates comparable to usual care.^{156,175-179} While pharmacological approaches, such as high-dose thiamine, have shown promise in small trials,¹⁹⁰⁻¹⁹³ these sit outside the non-pharmacological counselling interventions considered here, although they support inclusion of nutrition screening and education within broader programs. However, current evidence is limited by small sample sizes, heterogeneous content, and predominant recruitment of patients in remission. Effects are promising but modest, and further research is required to establish long-term benefits and applicability in active disease. By integrating fatigue management into routine assessments, IBD nurses act as the primary drivers of patient-centred care, ensuring that these specialized programs are both accessible and effective.

Statement 14. Inflammatory bowel disease nurses should routinely assess sexual function, provide counselling and education, and facilitate referral of patients experiencing sexual dysfunction to a specialist [EL3]

Inflammatory bowel disease nurses play an important role in the routine assessment of sexual function, particularly among perioperative patients and those experiencing active disease, as early identification can enable timely diagnosis and treatment of sexual dysfunction.¹⁹⁴ Preliminary evidence suggests that psychological interventions may be beneficial in alleviating sexual dysfunction. An 8-week, IBD-specific CBT

program delivered by a clinical psychologist demonstrated significant improvements in sexual functioning following the intervention period.¹⁹⁵ In contrast, a group cognitive behavioral psychotherapy intervention showed no significant effect on sexual function; however, the RCT may have been insufficiently powered to detect meaningful changes.³⁰ An observational study indicated that adherence to a Mediterranean diet, along with better physical and mental health, was protective against sexual dysfunction, particularly in females.¹⁹⁶ Supporting this, a multifaceted wellness program incorporating virtual healthy living classes and wellness coaching produced a significant positive effect on sexual function in women with IBD.¹⁹⁷ Although the evidence remains limited, IBD nurses should routinely assess sexual function using validated, gender- and IBD-specific tools and provide counselling and education on healthy lifestyle choices for patients experiencing sexual dysfunction and facilitate referrals to appropriate specialist members of the MDT (e.g., psychologist, sexologist, specialists in pelvic floor dysfunction or gynecologists), as appropriate and if available.¹⁹⁴

Statement 15. Inflammatory bowel disease nurses may address preconception and fertility concerns and provide accessible education to increase reproductive knowledge and improve emotional health in patients with IBD [EL4]

Suboptimal patient knowledge contributes to pregnancy avoidance, voluntary childlessness, and medication discontinuation during pregnancy.¹⁹⁸ Reported evidence recommends proactive pre-conception counselling, preferably starting at the time of IBD diagnosis in patients of childbearing age and 3-6 months prior to attempts at conception.¹⁹⁹ Fertility concerns, fetal safety of medications, IBD heritability, and disease control should be discussed.¹⁹⁸

As disease heritability is one of the greatest concerns of people with IBD, this topic requires special attention during pre-conception counselling.²⁰⁰ Although a positive family history is not the only consideration, the risk of IBD development in the child is increased (particularly for CD) and is much greater when both parents are affected.^{199,200}

Achieving and maintaining remission at the time of conception and during pregnancy reduces the risk of complications for both mother and fetus.²⁰¹ The IBD nurse should highlight the importance of disease monitoring and offer timely reviews to minimize relapses and early referral to the MDT for therapy adjustment.^{201,202} Educational intervention provided by the IBD nurse on IBD and pregnancy promotes reproductive knowledge and IBD medication adherence during pregnancy.¹⁹⁴

A Korean study revealed that a pre-conception educational program developed and provided by nurses and including small-group sessions and individual tele-coaching can improve IBD-related pregnancy knowledge and confidence in IBD self-management and was effective in relieving IBD-related anxiety.²⁰³

Most IBD medications do not impact fertility; only sulfasalazine can cause reversible sperm abnormality.²⁰⁴ Preconception counselling should address the negative impact of disease activity on fertility; advice on the importance of achieving clinical remission, which may improve chances of conception in both male and female patients, should be provided.²⁰²

Ileal pouch–anal anastomosis is often cited as a risk factor for infertility, particularly in females.¹⁹⁹ A laparoscopic approach seems to be associated with lower infertility, most likely due to reduced pelvic adhesions.¹⁹⁹ The IBD nurse should advocate for women with pregnancy desire to discuss surgical options within the MDT.²⁰⁵ Laparoscopic surgery and ileorectal anastomosis should be considered in suitable patients after careful evaluation as a fertility-sparing option.²⁰⁵

Once pregnant, women with IBD have comparable chances of achieving a live birth compared with women in the general population who underwent assisted reproductive technology.¹⁹⁹ The IBD nurse may identify the need for referrals for fertility therapy during the nurse consultation, which may subsequently be raised with the medical team.²⁰⁶

Statement 16. Inflammatory bowel disease nurses should inform patients with IBD who are pregnant on the impact of disease activity, delivery mode, postpartum, breastfeeding, and newborn vaccination [EL4]

Pregnant or postpartum women with IBD on advanced therapies should be managed by health care professionals with relevant expertise on IBD and pregnancy.²⁰⁷ The care should be coordinated between obstetrics and the IBD unit to ensure that the patient does not receive conflicting medical advice from the respective services.²⁰⁷ A joint pregnancy clinic with a dedicated gastroenterologist, obstetricians specializing in high-risk pregnancies, colorectal surgeons, IBD nurses, dietitians, and midwives is advised for the management of women with IBD presenting features associated with poor disease course.²⁰² The IBD nurse has a fundamental role in liaising with the gastroenterologist and obstetrician whilst supporting the patient.^{199,206}

Dedicated in-person or online educational programs improve not only the patient's IBD-specific pregnancy knowledge and medication adherence but also reduce anxiety about actively facing pregnancy.^{201,203} Inadequate knowledge is associated with riskier illness-related behaviors and fear²⁰¹; topics to be addressed should include drug safety, delivery mode, breastfeeding, and newborn vaccinations.²⁰⁸ Most IBD medications, including advanced therapies, are considered safe and can be continued during pregnancy to maintain remission.¹⁹⁹ However, since specific IBD medications (e.g., methotrexate, Janus-kinase inhibitors, and sphingosine-1-phosphate receptor modulators) are contraindicated in pregnancy, a thorough medication review prior to conception is recommended.²⁰²

Models of shared decision making should be employed when counselling patients regarding mode of delivery, as this will reduce patient uncertainty and anxiety.²⁰⁷ Vaginal delivery is recommended provided there are no obstetric contraindications.¹⁹⁹ Caesarean section would only be considered in the presence of an ileoanal pouch anastomosis and complex active perianal disease.¹⁹⁹

Breast milk provides ideal nutrition, has positive effects on the immune system of the newborn, and may protect against development of IBD.²⁰⁷ The IBD nurse should encourage breastfeeding and provide advice on medication safety.²⁰⁰ Drugs that are considered low-risk during pregnancy are also considered low-risk during breastfeeding and thus can be continued.²⁰²

Inactivated vaccines are recommended according to national guidelines, as their effectiveness and safety seem to be

favourable.¹⁹⁹ In children exposed in utero to biologics, live-attenuated vaccines should be withheld within the first year of life.¹⁹⁹ Improving patient knowledge and confidence for better disease management during pregnancy and the postpartum period should be the focus of future studies and specifically assess the effects of structured education programs delivered by IBD nurses.

Statement 17. Inflammatory bowel disease nurses should create a welcoming and inclusive environment for all patients, provide education that respects sexual orientation and gender identity, and help sexual and gender minority patients access the multidisciplinary care and support needed [EL5]

Inflammatory bowel disease nurses play a key role in fostering an inclusive environment for sexual and gender minority (SGM) individuals with IBD. Limited evidence exists regarding SGM individuals with IBD, as sexual orientation and gender identity (SOGI) data are often not collected or reported, thereby restricting disease-related insights in this cohort.^{209,210} However, emerging research²¹¹ indicates that cisgender men, cisgender women, and transgender and gender-diverse individuals with IBD may experience sex or gender differences (or both) in core symptoms, such as fatigue and anxiety, suggesting that tailored symptom management may be warranted. Furthermore, higher mental-health comorbidity has been reported among SGM individuals with IBD, which likely impacts QoL and care engagement.²¹² It is recommended that IBD nurses incorporate routine, sensitive SOGI data collection; use gender-affirming, inclusive language and communication; provide education that respects SOGI; and help SGM patients access the multidisciplinary care and support needed (e.g., for fertility or surgical planning). However, IBD clinicians require education and training in gender-affirming care, and further robust research involving inclusive samples is warranted.²¹³

Statement 18. Inflammatory bowel disease nurses should identify and regularly assess the evolving educational needs of newly diagnosed patients with IBD, provide timely and ongoing individualized education, and facilitate peer support [EL3]

Inflammatory bowel disease nurses play a pivotal role in identifying and regularly assessing the evolving educational needs of newly diagnosed patients with IBD, providing timely and individualized education, and facilitating peer support. Only two RCTs have specifically evaluated the effectiveness of educational interventions in newly diagnosed patients with IBD. A small feasibility study found that a web-based educational resource focusing on food-related issues led to improvements in food-related QoL and some psychological outcomes in patients diagnosed within the past year.²¹⁴ Another study evaluating an IBD nurse-coordinated, multiprofessional, group-based education intervention did not demonstrate significant differences in psychological well-being between the control and intervention groups; however, it was highly valued by patients diagnosed within the previous 2 years.²¹⁵

Research^{216–219} including newly diagnosed patients with IBD in a wider sample has evaluated educational videos,²¹⁶ adaptation training,²¹⁷ integrated medical and psychological/

psychosocial group-based intervention programs,²¹⁸ and a therapeutic education program²¹⁹; however, the samples were not stratified by disease duration. A subgroup analysis demonstrated a statistically significant improvement in HRQoL and coping ability in those with a short disease course (≤ 3 years) after receiving an education and group therapy intervention.²¹⁸ A standardized therapeutic educational program also found a significant increase in skills and knowledge compared with the control group in a large multi-center RCT that included patients with a recent diagnosis (< 6 months).²¹⁹

Inflammatory bowel disease nurses, as part of the MDT, should provide timely and ongoing individualized education that incorporates peer support and addresses the unique needs, preferences, and goals of newly diagnosed patients with IBD. The limited evidence base¹¹⁸ highlights the need for IBD nurses to contribute to knowledge generation by formally evaluating educational programs implemented in practice using scientific methods, such as experimental or quasi-experimental methods and standardized and validated patient-reported outcome measures.²²⁰

Statement 19. Inflammatory bowel disease nurses are recommended to use individualized digital-health technologies as supportive resources to enhance treatment adherence and reduce hospital visits [EL4]

Digital-health technologies are increasingly being adopted to support clinical practice, as evidenced by the growing body of high-level research in this area. An umbrella review²²¹ of nine systematic reviews of RCTs found that digital-health technologies do not lead to better clinical outcomes in maintaining IBD remission or reducing relapse rates; however, these technologies could be used as an adjuvant resource that contributes towards treatment adherence and reducing hospital visits. There was considerable heterogeneity in the digital interventions evaluated, including web-based applications, telephone consultations, emails, text messages, videos, remote-monitoring platforms, tele-education, virtual clinics, and online self-management programs. Evidence suggests that digital-health technologies do not significantly affect disease activity^{222–226} or remission rates.^{222,224} Nevertheless, some improvements have been reported in QoL^{222,224} and disease-related knowledge,²²⁴ with stronger evidence supporting improvements in medication adherence^{223,226–228} and reductions in hospital visits,^{222,225,226,228,229} including outpatient and emergency visits, albeit with variable effect sizes.²²¹ The substantial heterogeneity across studies and high risk of bias highlight the need for standardization of digital interventions and for more robust, large-scale RCTs to confirm their effectiveness and identify patient subgroups most likely to benefit. The adoption of digital-health technologies in IBD care is expected to grow with the emergence and integration of artificial intelligence into these tools. Artificial intelligence, including generative and machine-learning models, is evolving as a transformative tool in IBD care through improved prognosis and personalized care. However, clinical integration depends on rigorous validation, standardized protocols, data transparency, and expert oversight to ensure reliability and safety.^{230–237} Furthermore, while no harmful effects of the use of digital-health technologies have yet been reported, concerns regarding equitable access, data security, and potential effects on clinical decision making require ongoing investigation.²²¹

As the patient's first contact, the IBD nurse provides advice and education and coordinates care by using different digital-health technologies, such as virtual clinics, videos, and tele-education.

Statement 20. Nurses new to IBD should engage in structured, competency-based mentoring programs to improve job satisfaction, retention, and patient outcomes [EL4]

The principles of structured and guided learning, which are fundamental to effective mentoring, are well-supported in the literature despite a current lack of direct evidence focused specifically on formal IBD nursing mentorship. Mizuno et al.²³⁸ demonstrated significant improvements in IBD-related knowledge through an e-learning educational program based on the Attention, Relevance, Confidence, and Satisfaction instructional design model, with high participant satisfaction and usability ratings. Similarly, Berry et al. reported that brief, targeted educational interventions significantly improved validated IBD knowledge scores (CCKNOW) among nurses, regardless of delivery modality.²³⁹

Moreover, Ohue and Menta²⁴⁰ showed that mentorship interventions incorporating CBT techniques effectively reduced burnout and turnover among nurses, highlighting the psychological and professional benefits of structured mentoring. These findings reinforce the importance of mentoring in fostering emotional well-being, self-efficacy, and retention factors closely linked to the delivery of safe, high-quality patient care.

The potential for structured mentoring to improve patient outcomes is driven by its ability to bolster the competence and well-being of the IBD nurse. Current evidence suggests that these frameworks ensure more consistent and confident nursing care, representing a vital investment in the clinical workforce even where direct IBD-specific data remain limited.

Conclusion

The landscape of IBD management is consistently evolving and the role of the IBD nurse is clearer and more established. The N-ECCO Consensus Statements provide a framework for IBD nurses regardless of geographic location to continue delivering high-quality and evidence-based care to IBD patients.

Acknowledgments

We would like to thank Justine Guldenpfennig and Nadine Steubesand for the literature search, and Torsten Karge for support with informatics and the online platform. We would like to express our gratitude to Benthe Bertelsen and Cristiano Consorte who proactively collaborated in the development of this Consensus as IFCCA patient representatives. We would also like to acknowledge the following colleagues who shared their feedback in the second online voting round: N-ECCO National Representatives: Martin Belovai, Carmen Bobnar Sekulic, Sofie Himpe, Cristina Lopez Sanchez, Else Mikkelsen, Tobias Mooslechner, Tadeja Polanc, and Fanny Stahl; ECCO National Representatives: Edmond Baghdasaryan, Andreas Blesl, Vadim Brjalin, Mihai Diculescu, Shahida Din, Piotr Eder, Pierre Ellul, Magdalena Gawron-Kiszka, Tatiana Jovic, Zeljko Krznaric, Juozas Kupcinskas, Hendrik Laja, Lieven Pouillon,

Aldis Pukitis, Elisabeth Schnoy, Konstantinos Soufleris, Svetlana Turcan, Sophie Vieujean, and Yamile Zabana; Additional Reviewers: Micheline Abou Saleh, Simone Breitenicher, Nallely Bueno Hernandez, Jie Chen, Bridgette Fraser, Marta Gallego Barrero, Antonietta Gerarda Gravina, Konstantinos Katsanos, Nikki Lembrechts, Heather Lennox, Raffaele Pellegrino, and Zahira Perez Martinez.

Supplementary material

Supplementary material is available at ECCO-JCC online.

Funding

This project was initiated, funded, and supported by ECCO.

Conflicts of interest

European Crohn's and Colitis Organisation has diligently maintained a disclosure policy of potential conflicts of interests. The conflict-of-interest declaration is based on a form used by the International Committee of Medical Journal Editors [ICMJE]. The conflicts-of-interest disclosures are not only stored at the ECCO Office and the editorial office of JCC, but are also open to public scrutiny on the ECCO website [<https://www.ecco-ibd.eu/about-ecco/ecco-disclosures.html>], providing a comprehensive overview of potential conflicts of interest of the authors.

Data availability statement

The data underlying this article are available in the article and in its online [Supplementary material](#).

References

- Delen S, Jaghult S, Blumenstein I, Pouillon L, Bossuyt P. Framework of IBD care delivery across ages. *J Crohns Colitis*. 2024;18:ii55-ii66. <https://doi.org/10.1093/ecco-jcc/fjae093>
- Fiorino G, Lytras T, Younge L, et al. Quality of care standards in inflammatory bowel diseases: a European Crohn's and Colitis Organisation [ECCO] position paper. *J Crohns Colitis*. 2020;14:1037-1048. <https://doi.org/10.1093/ecco-jcc/fjaa023>
- O'Connor M, Bager P, Duncan J, et al. N-ECCO consensus statements on the European nursing roles in caring for patients with Crohn's disease or ulcerative colitis. *J Crohns Colitis*. 2013;7:744-764. <https://doi.org/10.1016/j.crohns.2013.06.004>
- Kemp K, Dibley L, Chauhan U, et al. Second N-ECCO consensus statements on the European nursing roles in caring for patients with Crohn's disease or ulcerative colitis. *J Crohns Colitis*. 2018;12:760-776. <https://doi.org/10.1093/ecco-jcc/jjy020>
- Prasad SS, Potter M, Keely S, Talley NJ, Walker MM, Kairuz T. Roles of healthcare professionals in the management of chronic gastrointestinal diseases with a focus on primary care: a systematic review. *JGH Open*. 2020;4:221-229. <https://doi.org/10.1002/jgh3.12235>
- Schoenfeld R, Nguyen GC, Bernstein CN. Integrated care models: optimizing adult ambulatory care in inflammatory bowel disease. *J Can Assoc Gastroenterol*. 2020;3:44-53. <https://doi.org/10.1093/jcag/gwy060>
- Massuger W, Moore GTC, Andrews JM, et al. Crohn's & Colitis Australia inflammatory bowel disease audit: measuring the quality of care in Australia. *Intern Med J*. 2019;49:859-866. <https://doi.org/10.1111/imj.14187>
- Coenen S, Weyts E, Vermeire S, et al. Effects of introduction of an inflammatory bowel disease nurse position on the quality of delivered care. *Eur J Gastroenterol Hepatol*. 2017;29:646-650. <https://doi.org/10.1097/MEG.0000000000000839>
- Karimi N, Sechi AJ, Harb M, et al. The effect of a nurse-led advice line and virtual clinic on inflammatory bowel disease service delivery: an Australian study. *Eur J Gastroenterol Hepatol*. 2021;33:e771-e6. <https://doi.org/10.1097/MEG.0000000000002249>
- Wolf DC, Jaganathan S, Burudpakdee C, et al. Adherence rates and health care costs in Crohn's disease patients receiving certolizumab pegol with and without home health nurse assistance: results from a retrospective analysis of patient claims and home health nurse data. *Patient Prefer Adherence*. 2018;12:869-878. <https://doi.org/10.2147/PPA.S148777>
- Correal EN, Leiva OB, Galguera AD, Barrero MG, Pastor ES, Gonzalo MFM. Nurse-led telephone advice line for patients with inflammatory bowel disease: a cross-sectional multicenter activity analysis. *Gastroenterol Nurs*. 2019;42:133-139. <https://doi.org/10.1097/SGA.0000000000000372>
- Yu N, Wu K, Samyue T, et al. Outcomes of a comprehensive specialist inflammatory bowel disease nursing service. *Inflamm Bowel Dis*. 2024;30:960-969. <https://doi.org/10.1093/ibd/izad145>
- Sack C, Phan VA, Grafton R, et al. A chronic care model significantly decreases costs and healthcare utilisation in patients with inflammatory bowel disease. *J Crohns Colitis*. 2012;6:302-310. <https://doi.org/10.1016/j.crohns.2011.08.019>
- Leach P, De Silva M, Mountifield R, et al. The effect of an inflammatory bowel disease nurse position on service delivery. *J Crohns Colitis*. 2014;8:370-374. <https://doi.org/10.1016/j.crohns.2013.09.018>
- Xu C, Xi W, Wu C, Liu L, Wang L. Effects of continuous nursing on the disease uncertainty, coping strategies and quality of sleep and life of patients with inflammatory bowel disease. *J Multidiscip Healthc*. 2023;16:2071-2080. <https://doi.org/10.2147/JMDH.S414104>
- Hawthorne AB, Glatter J, Blackwell J, et al.; IBD UK Board IBD UK Task & Finish Group. Inflammatory bowel disease patient-reported quality assessment should drive service improvement: a national survey of UK IBD units and patients. *Aliment Pharmacol Ther*. 2022;56:625-645. <https://doi.org/10.1111/apt.17042>
- Shi X, Geng L. Chronic illness trajectory-based nursing intervention improves the self-care abilities of patients with inflammatory bowel disease. *Am J Transl Res*. 2024;16:2579-2588. <https://doi.org/10.62347/QE002698>
- Bokemeyer B, Plachta-Danielzik S, Steiner IM, et al. Inflammatory bowel disease (IBD) patients with impaired quality of life on biologic therapy benefit from the support of an IBD nurse specialist: results of a randomised controlled trial in Germany (IBD(BIO-ASSIST) study). *Aliment Pharmacol Ther*. 2024;59:1082-1095. <https://doi.org/10.1111/apt.17926>
- Fiorino G, Allocca M, Chaparro M, et al. 'Quality of Care' standards in inflammatory bowel disease: a systematic review. *J Crohns Colitis*. 2019;13:127-137. <https://doi.org/10.1093/ecco-jcc/jjy140>
- Yang C, Hsu T, Chen Y, Huang S, Yen H. Attitudes to medication and effects of IBD nursing service among patients with inflammatory bowel disease in Taiwan. *Adv in Digestive Medicine*. 2024;11:162-169. <https://doi.org/10.1002/aid2.13383>
- Yanai H, Sharar Fischler T, Goren I, et al. A real-world prospective cohort study of patients with newly diagnosed Crohn's disease

- treated by a multidisciplinary team: 1-year outcomes. *Crohn's Colitis* 360. 2023;5:otad064.
22. Zhou Y, Li C, Chen M, Gao C. Impact of continuous care on quality of life of patients with inflammatory bowel disease based on multi-disciplinary cooperation on WeChat platform. *Technol Health Care*. 2024;32:4909-4918. <https://doi.org/10.3233/THC-232032>
 23. Kapasi R, Glatter J, Lamb CA, et al. Consensus standards of health-care for adults and children with inflammatory bowel disease in the UK. *Frontline Gastroenterol*. 2020;11:178-187. <https://doi.org/10.1136/flgastro-2019-101260>
 24. Lores T, Goess C, Mikocka-Walus A, et al. Integrated psychological care reduces health care costs at a hospital-based inflammatory bowel disease service. *Clin Gastroenterol Hepatol*. 2021;19:96-103.e3. <https://doi.org/10.1016/j.cgh.2020.01.030>
 25. Romano D, Chesterman S, Fuller-Tyszkiewicz M, et al. Feasibility, acceptability, and preliminary efficacy of acceptance commitment therapy for adults living with inflammatory bowel disease and distress. *Inflamm Bowel Dis*. 2024;30:911-921. <https://doi.org/10.1093/ibd/izad122>
 26. Ferreira C, Pereira J, Skvarc D, et al. Randomized controlled trial of an acceptance and commitment therapy and compassion-based group intervention for persons with inflammatory bowel disease: the LIFEwithIBD intervention. *Front Psychol*. 2024;15:1367913. <https://doi.org/10.3389/fpsyg.2024.1367913>
 27. Goren G, Schwartz D, Friger M, et al. Gender differences in coping strategies and life satisfaction following cognitive-behavioral and mindfulness-based intervention for Crohn's disease: a randomized controlled trial. *J Clin Med*. 2025;14:1569. <https://doi.org/10.3390/jcm14051569>
 28. Wilkin K, Evans S, Van Niekerk L, et al. Moving towards acceptance and values: a qualitative study of ACTforIBD compared to IBD psychoeducation. *J Clin Psychol Med Settings*. 2024;31:245-257. <https://doi.org/10.1007/s10880-023-09999-5>
 29. Gracie DJ, Irvine AJ, Sood R, Mikocka-Walus A, Hamlin PJ, Ford AC. Effect of psychological therapy on disease activity, psychological comorbidity, and quality of life in inflammatory bowel disease: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol*. 2017;2:189-199. [https://doi.org/10.1016/S2468-1253\(16\)30206-0](https://doi.org/10.1016/S2468-1253(16)30206-0)
 30. Kalogeropoulou M, Karaivazoglou K, Konstantopoulou G, et al. The impact of group cognitive behavioral psychotherapy on disease severity and psychosocial functioning in patients with inflammatory bowel disease: a randomized controlled study. *J Crohn's Colitis*. 2025;19:jjae144.
 31. Naude C, Skvarc D, Biurra YC, et al. An online mindfulness-based intervention for adults with Inflammatory Bowel Disease & psychological distress: a feasibility randomized controlled trial of the Mind4IBD program. *J Psychosom Res*. 2025;189:111984. <https://doi.org/10.1016/j.jpsychores.2024.111984>
 32. Ter Avest MM, van Velthoven ASM, Speckens AEM, et al. Effectiveness of mindfulness-based cognitive therapy in reducing psychological distress and improving sleep in patients with inflammatory bowel disease: study protocol for a multicentre randomised controlled trial (MindIBD). *BMC Psychol*. 2023;11:183. <https://doi.org/10.1186/s40359-023-01127-0>
 33. Bauer N, Löffler C, Oeznur O, et al. Evaluation of a multimodal stress management and comprehensive lifestyle modification program on quality of life and gastrointestinal symptoms in patients with Crohn's disease: a randomized controlled pilot trial with 9-month follow-up. *Digestion*. 2024;105:201-212. <https://doi.org/10.1159/000536659>
 34. Lores T, Goess C, Mikocka-Walus A, et al. Integrated psychological care is needed, welcomed and effective in ambulatory inflammatory bowel disease management: evaluation of a new initiative. *J Crohn's Colitis*. 2019;13:819-827. <https://doi.org/10.1093/ecco-jcc/jjz026>
 35. Mikocka-Walus A, Bampton P, Hetzel D, Hughes P, Esterman A, Andrews JM. Cognitive-behavioural therapy has no effect on disease activity but improves quality of life in subgroups of patients with inflammatory bowel disease: a pilot randomised controlled trial. *BMC Gastroenterol*. 2015;15:54. <https://doi.org/10.1186/s12876-015-0278-2>
 36. Reggev S, Goren G, Schwartz D, et al. A randomized controlled trial of the effectiveness of individualized cognitive behavioral mindfulness intervention on disease symptoms and psycho-social outcomes in patients with Crohn's disease. *Gastroenterology*. 2020;158:S-424-S-425. [https://doi.org/10.1016/S0016-5085\(20\)31750-9](https://doi.org/10.1016/S0016-5085(20)31750-9)
 37. Schwartz D, Goren G, Perpinial P, et al. Mindfulness-based stress reduction in adult patients with active Crohn's disease: preliminary findings based on the subjective units of distress scale: an IIRN study. *Journal of Crohn's & Colitis*. 2019;13:S440-S441. <https://doi.org/10.1093/ecco-jcc/jjy222.768>
 38. Lavelle J, Storan D, Eswara Murthy V, De Dominicis N, Mulcahy HE, McHugh L. Brief and telehealth acceptance and commitment therapy (ACT) interventions for stress in inflammatory bowel disease (IBD): a series of single case experimental design (SCED) studies. *J Clin Med*. 2022;11:2757. <https://doi.org/10.3390/jcm11102757>
 39. Ford MK, Iuliano A, Walters TD, et al. Bolstering connectedness through peer support: randomized-controlled trial of a web-based peer support program for adolescents with inflammatory bowel disease. *Health Care Transit*. 2025;3:100085. <https://doi.org/10.1016/j.hctj.2024.100085>
 40. Berding A, Witte C, Gottschald M, et al. Beneficial effects of education on emotional distress, self-management, and coping in patients with inflammatory bowel disease: a prospective randomized controlled study. *Inflamm Intest Dis*. 2017;1:182-190. <https://doi.org/10.1159/000452989>
 41. Morvillo C, Vinci K, Hedenschoug L, et al. Risks and safety of advanced therapies and biologics in inflammatory bowel disease: a review for nurses. *Gastroenterol Nurs*. 2020;43:E159-E171. <https://doi.org/10.1097/SGA.0000000000000523>
 42. Park J, Park S, Lee SA, Park SJ, Cheon JH. Improving the care of inflammatory bowel disease (IBD) patients: perspectives and strategies for IBD center management. *Korean J Intern Med*. 2021;36:1040-1048. <https://doi.org/10.3904/kjim.2021.114>
 43. Armuzzi A, Avedano L, Greveson K, Kang T. Nurses are critical in aiding patients transitioning to biosimilars in inflammatory bowel disease: education and communication strategies. *J Crohn's Colitis*. 2019;13:259-266. <https://doi.org/10.1093/ecco-jcc/jjy150>
 44. Battat R, Galati JS, Lukin D, et al. A quality improvement initiative is associated with reduced time to administer biologics and small molecules and emergency room visits in inflammatory bowel disease. *J Clin Gastroenterol*. 2022;56:e176-e82. <https://doi.org/10.1097/MCG.0000000000001535>
 45. Kruger AJ, Dormont F, Capit N, et al. Biologic switch timing and risk of infection in patients with ulcerative colitis/Crohn's disease: a retrospective study. *Clin Gastroenterol Hepatol*. 2025;23:2253-2262. <https://doi.org/10.1016/j.cgh.2025.01.028>
 46. Rubin DT, Mittal M, Davis M, Johnson S, Chao J, Skup M. Impact of a patient support program on patient adherence to adalimumab and direct medical costs in Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriasis, psoriatic arthritis, and ankylosing

- spondylitis. *J Manag Care Spec Pharm.* 2017;23:859-867. <https://doi.org/10.18553/jmcp.2017.16272>
47. Abreu C, Sarmiento A, Magro F. Screening, prophylaxis and counselling before the start of biological therapies: a practical approach focused on IBD patients. *Dig Liver Dis.* 2017;49:1289-1297. <https://doi.org/10.1016/j.dld.2017.09.002>
 48. Engel T, Ungar B, Ben-Haim G, Levhar N, Eliakim R, Ben-Horin S. Re-phrasing the question: a simple tool for evaluation of adherence to therapy in patients with inflammatory bowel disease. *United European Gastroenterol J.* 2017;5:880-886. <https://doi.org/10.1177/2050640616687838>
 49. Brixner D, Rubin DT, Mease P, et al. Patient support program increased medication adherence with lower total health care costs despite increased drug spending. *J Manag Care Spec Pharm.* 2019;25:770-779. <https://doi.org/10.18553/jmcp.2019.18443>
 50. Lai C, Sceats LA, Qiu W, Park KT, Morris AM, Kin C. Patient decision-making in severe inflammatory bowel disease: the need for improved communication of treatment options and preferences. *Colorectal Dis.* 2019;21:1406-1414. <https://doi.org/10.1111/codi.14759>
 51. Simian D, Flores L, Quera R, et al. The Role of an Inflammatory Bowel Disease Nurse in the Follow-Up of Patients From a Latin American Inflammatory Bowel Disease Program. *Gastroenterol Nurs.* 2020;43:E16-E23. <https://doi.org/10.1097/SGA.0000000000000436>
 52. Almario CV, van Deen WK, Chen M, et al. Interactive inflammatory bowel disease biologics decision aid does not improve patient outcomes over static education: results from a randomized trial. *Am J Gastroenterol.* 2022;117:1508-1518. <https://doi.org/10.14309/ajg.0000000000001866>
 53. Kang J, Su J, Wang J, et al. An education-based telehealth group improves the management and clinical outcomes of patients with inflammatory bowel disease in China (THEIM study). *United European Gastroenterol J.* 2023;11:960-972. <https://doi.org/10.1002/ueg2.12470>
 54. Srinivasan A, van Langenberg DR, Little RD, Sparrow MP, De Cruz P, Ward MG. A virtual clinic increases anti-TNF dose intensification success via a treat-to-target approach compared with standard outpatient care in Crohn's disease. *Aliment Pharmacol Ther.* 2020;51:1342-1352. <https://doi.org/10.1111/apt.15742>
 55. Ajani ALA, Frank D, Raedler A, Spehlmann ME. Information needs of patients with inflammatory bowel disease in the digital era: a 20-year longitudinal study. *J Clin Med.* 2025;14:3939. <https://doi.org/10.3390/jcm14113939>
 56. Bossuyt P, Pouillon L, Claeys S, et al. Ultra-proactive therapeutic drug monitoring of infliximab based on point of care testing in inflammatory bowel disease: results of a pragmatic trial. *J Crohns Colitis.* 2022;16:199-206. <https://doi.org/10.1093/ecco-jcc/fjab127>
 57. Colombel JF, Panaccione R, Bossuyt P, et al. A treat to target approach decreases the rate of cd-related adverse outcomes versus a clinical approach in patients with moderate to severely active Crohn's disease: data from CALM 2017 ACG Governors Award for Excellence in Clinical Research: 598. *American J of Gastroenterol.* 2017;112:S321.
 58. Rinaldi A, Katsaros D, Hawthorne J, et al. The current paradigm for biologic initiation: a mixed-methods exploration of practices, unmet needs, and innovation opportunities in self-injection training. *Expert Opin Drug Deliv.* 2021;18:1151-1168. <https://doi.org/10.1080/17425247.2021.1912009>
 59. Park J, Yoon H, Shin CM, Park YS, Kim N, Lee DH. Higher levels of disease-related knowledge reduce medical acceleration in patients with inflammatory bowel disease. *PLoS One.* 2020;15:e0233654. <https://doi.org/10.1371/journal.pone.0233654>
 60. Ebhabha V, Morrissey H, Ball P. Comparing patient preference between at-home and in-hospital settings: systematic review and meta-analysis on injectable medications. *Arch Pharm Pract.* 2023;14:98-111. <https://doi.org/10.51847/VKorxIT0tX>
 61. Chan P, McNamara J, Vernon-Roberts A, et al. Systematic review: practices and programs in inflammatory bowel disease transition care. *Inflamm Bowel Dis.* 2025;31:1404-1418. <https://doi.org/10.1093/ibd/izae190>
 62. Eros A, Soos A, Hegyi P, et al. Spotlight on transition in patients with inflammatory bowel disease: a systematic review. *Inflamm Bowel Dis.* 2020;26:331-346.
 63. García-Rodríguez F, Raygoza-Cortez K, Moreno-Hernandez L, et al. Outcomes of transitional care programs on adolescent chronic inflammatory systemic diseases: systematic review and meta-analyses. *Pediatr Rheumatol.* 2022;20:15. <https://doi.org/10.1186/s12969-022-00670-1>
 64. Mollah T, Lee D, Giles E. Impact of a new young adult inflammatory bowel disease transition clinic on patient satisfaction and clinical outcomes. *J Paediatr Child Health.* 2022;58:1053-1059. <https://doi.org/10.1111/jpc.15907>
 65. Rubín de Célix C, Martín-de-Carpi J, Pujol-Muncunill G, et al. Benefits of paediatric to adult transition programme in inflammatory bowel disease: the BUTTERFLY Study of GETECCU and SEGHN. *JCM.* 2023;12:4813. <https://doi.org/10.3390/jcm12144813>
 66. Rohatinsky N, Risling T, Hellsten LM, Kumaran M. Inflammatory bowel disease nurses' perspectives: prioritizing adolescent transition readiness factors. *J Pediatr Nurs.* 2020;55:29-39. <https://doi.org/10.1016/j.pedn.2020.06.011>
 67. Sattoe JNT, Peeters MAC, Haitsma J, van Staa A, Wolters VM, Escher JC. Value of an outpatient transition clinic for young people with inflammatory bowel disease: a mixed-methods evaluation. *BMJ Open.* 2020;10:e033535. <https://doi.org/10.1136/bmjopen-2019-033535>
 68. Velonias G, Conway G, Andrews E, et al. Older age- and health-related quality of life in inflammatory bowel diseases. *Inflamm Bowel Dis.* 2017;23:283-288. <https://doi.org/10.1097/MIB.0000000000001008>
 69. Ananthakrishnan AN, Nguyen GC, Bernstein CN. AGA clinical practice update on management of inflammatory bowel disease in elderly patients: expert review. *Gastroenterology.* 2021;160:445-451. <https://doi.org/10.1053/j.gastro.2020.08.060>
 70. Sousa P, Bertani L, Rodrigues C. Management of inflammatory bowel disease in the elderly: a review. *Dig Liver Dis.* 2023;55:1001-1009. <https://doi.org/10.1016/j.dld.2022.12.024>
 71. Hong SJ, Katz S. The elderly IBD patient in the modern era: changing paradigms in risk stratification and therapeutic management. *Ther Adv Gastroenterol.* 2021;14:17562848211023399. <https://doi.org/10.1177/17562848211023399>
 72. Calafat M, Kochar B, Ananthakrishnan AN. A comprehensive review of geriatric syndromes and assessment in older adults with inflammatory bowel diseases. *Clin Gastroenterol Hepatol.* 2025;23:1088-1101. <https://doi.org/10.1016/j.cgh.2024.09.042>
 73. Butter M, Weiler S, Biedermann L, et al. Clinical manifestations, pathophysiology, treatment and outcome of inflammatory bowel diseases in older people. *Maturitas.* 2018;110:71-78. <https://doi.org/10.1016/j.maturitas.2018.01.015>
 74. Rohatinsky N, Russell B, Read KB. The experiences of older adults living with inflammatory bowel disease: a scoping review.

- Gastroenterol Nurs.* 2023;46:296-308. <https://doi.org/10.1097/SGA.0000000000000737>
75. Asscher VER, Waars SN, van der Meulen-de Jong AE, et al. Deficits in geriatric assessment associate with disease activity and burden in older patients with inflammatory bowel disease. *Clin Gastroenterol Hepatol.* 2022;20:e1006-e21. <https://doi.org/10.1016/j.cgh.2021.06.015>
 76. Sturm A, Maaser C, Mendall M, et al. European Crohn's and Colitis Organisation Topical review on IBD in the elderly. *J Crohns Colitis.* 2017;11:263-273. <https://doi.org/10.1093/ecco-jcc/jjw188>
 77. Davis SP, McInerney R, Fisher S, Davis BL. Therapeutic needs of older adults with inflammatory bowel disease (IBD): a systematic review. *Gastroenterol Insights.* 2024;15:835-864. <https://doi.org/10.3390/gastroent15030059>
 78. Hruz P, Juillerat P, Kullak-Ublick GA, Schoepfer AM, Mantzaris GJ, Rogler G; on behalf of Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology. Management of the Elderly Inflammatory Bowel Disease Patient. *Digestion.* 2020;101:105-119. <https://doi.org/10.1159/000503099>
 79. Qazi T, Farraye FA. Sleep disturbances in the elderly patient with inflammatory bowel disease. *Curr Treat Options Gastroenterol.* 2019;17:470-491. <https://doi.org/10.1007/s11938-019-00258-x>
 80. Rohatinsky N, Chauhan U, Currie B, et al. Older adults with inflammatory bowel disease in Canada: a mixed-methods exploratory study of care experiences and health-related quality of life. *Gastroenterol Nurs.* 2024;47:41-51. <https://doi.org/10.1097/SGA.0000000000000776>
 81. Asscher VER, Lee-Kong FVY, Kort ED, van Deudekom FJ, Mooijjaart SP, Maljaars PWJ. Systematic review: components of a comprehensive geriatric assessment in inflammatory bowel disease—a potentially promising but often neglected risk stratification. *J Crohns Colitis.* 2019;13:1418-1432. <https://doi.org/10.1093/ecco-jcc/jjz082>
 82. Rohatinsky N, Tooke N, Fowler S, et al. Identification and prioritization of patient-centred strategies to enhance IBD-related care for older adults: a modified Delphi approach. *J Can Assoc Gastroenterol.* 2024;7:384-392. <https://doi.org/10.1093/jcag/gwae021>
 83. van Noort HHJ, Witteman BJM, Vermeulen H, Huisman-de Waal G; Basic Care Revisited Research Group. An outpatient nursing nutritional intervention to prehabilitate undernourished patients for surgery: a multicentre, cluster-randomised pilot study. *Clin Nutr.* 2020;39:2420-2427. <https://doi.org/10.1016/j.clnu.2019.11.038>
 84. Brennan GT, Ha I, Hogan C, et al. Does preoperative enteral or parenteral nutrition reduce postoperative complications in Crohn's disease patients: a meta-analysis. *Eur J Gastroenterol Hepatol.* 2018;30:997-1002. <https://doi.org/10.1097/MEG.0000000000001162>
 85. Krasnovsky L, Weber AT, Gershuni V, Pettke E, Lewis JD. Preoperative exclusive enteral nutrition is associated with reduced skin and soft tissue and intra-abdominal infections in patients with Crohn's disease undergoing intestinal surgery: results from a meta-analysis. *Inflamm Bowel Dis.* 2024;30:2105-2114. <https://doi.org/10.1093/ibd/izad304>
 86. Svols V, Gordon H, Lomer MCE, et al. ECCO consensus on dietary management of inflammatory bowel disease. *J Crohns Colitis.* 2025;19:jjaf122.
 87. González-Huix F, de León R, Fernández-Bañares F, et al. Polymeric enteral diets as primary treatment of active Crohn's disease: a prospective steroid controlled trial. *Gut.* 1993;34:778-782. <https://doi.org/10.1136/gut.34.6.778>
 88. Zoli G, Carè M, Parazza M, et al. A randomized controlled study comparing elemental diet and steroid treatment in Crohn's disease. *Aliment Pharmacol Ther.* 1997;11:735-740. <https://doi.org/10.1046/j.1365-2036.1997.t01-1-00192.x>
 89. Chu MKW, Day AS, Broad L, Costello SP, Edwards S, Bryant RV. Meta-analysis: exclusive enteral nutrition in adults with ulcerative colitis. *Aliment Pharmacol Ther.* 2025;61:756-775. <https://doi.org/10.1111/apt.18495>
 90. Jatkowska A, White B, Gkikas K, Seenan JP, MacDonald J, Gerasimidis K. Partial enteral nutrition in the management of Crohn's disease: a systematic review and meta-analysis. *J Crohns Colitis.* 2025;19:jjae177. <https://doi.org/10.1093/ecco-jcc/jjae177>
 91. Gleave A, Shah A, Tahir U, et al. Using diet to treat inflammatory bowel disease: a systematic review. *Am J Gastroenterol.* 2025;120:83-97. <https://doi.org/10.14309/ajg.0000000000002973>
 92. Limketkai BN, Godoy-Brewer G, Parian AM, et al. Dietary interventions for the treatment of inflammatory bowel diseases: an updated systematic review and meta-analysis. *Clin Gastroenterol Hepatol.* 2023;21:2508-2525 e10. <https://doi.org/10.1016/j.cgh.2022.11.026>
 93. Correia I, Oliveira PA, Antunes ML, Raimundo MDG, Moreira AC. Is there evidence of Crohn's disease exclusion diet (CDED) in remission of active disease in children and adults? A systematic review. *Nutrients.* 2024;16:987. <https://doi.org/10.3390/nu16070987>
 94. Pasta A, Formisano E, Calabrese F, et al. The use of the Crohn's disease exclusion diet (CDED) in adults with Crohn's disease: a randomized controlled trial. *Eur J Clin Invest.* 2025;55:e14389. <https://doi.org/10.1111/eci.14389>
 95. Yanai H, Levine A, Hirsch A, et al. The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial. *Lancet Gastroenterol Hepatol.* 2022;7:49-59. [https://doi.org/10.1016/S2468-1253\(21\)00299-5](https://doi.org/10.1016/S2468-1253(21)00299-5)
 96. Godny L, Elial-Fatal S, Arrouasse J, et al. Mechanistic implications of the Mediterranean diet in patients with newly diagnosed Crohn's disease: multiomic results from a prospective cohort. *Gastroenterology.* 2025;168:952-964 e2. <https://doi.org/10.1053/j.gastro.2024.12.031>
 97. Lewis JD, Sandler RS, Brotherton C, et al.; DINE-CD Study Group. A randomized trial comparing the specific carbohydrate diet to a Mediterranean diet in adults with Crohn's Disease. *Gastroenterology.* 2021;161:837-852 e9. <https://doi.org/10.1053/j.gastro.2021.05.047>
 98. Day AS, Yao CK, Costello SP, et al. Therapeutic potential of the 4 strategies to Sulfide-Reduction (4-SURE) diet in adults with mild to moderately active ulcerative colitis: an open-label feasibility study. *J Nutr.* 2022;152:1690-1701. <https://doi.org/10.1093/jn/nxac093>
 99. Sarbagili Shabat C, Scaldaferrì F, Zittan E, et al. Use of faecal transplantation with a novel diet for mild to moderate active ulcerative colitis: the CRAFT UC randomised controlled trial. *J Crohns Colitis.* 2022;16:369-378. <https://doi.org/10.1093/ecco-jcc/jjab165>
 100. Hirai F, Takeda T, Takada Y, et al. Efficacy of enteral nutrition in patients with Crohn's disease on maintenance anti-TNF-alpha antibody therapy: a meta-analysis. *J Gastroenterol.* 2020;55:133-141. <https://doi.org/10.1007/s00535-019-01634-1>
 101. Yang H, Feng R, Li T, et al. Systematic review with meta-analysis of partial enteral nutrition for the maintenance of remission in Crohn's disease. *Nutr Res.* 2020;81:7-18. <https://doi.org/10.1016/j.nutres.2020.06.006>
 102. Albenberg L, Brensinger CM, Wu Q, et al. A diet low in red and processed meat does not reduce rate of Crohn's disease flares.

- Gastroenterology*. 2019;157:128-136 e5. <https://doi.org/10.1053/j.gastro.2019.03.015>
103. Jowett SL, Seal CJ, Pearce MS, et al. Influence of dietary factors on the clinical course of ulcerative colitis: a prospective cohort study. *Gut*. 2004;53:1479-1484. <https://doi.org/10.1136/gut.2003.024828>
 104. Sarbagili-Shabat C, Zelber-Sagi S, Fliss Isakov N, et al. High ultra-processed food consumption is associated with clinical exacerbation in patients with Crohn's disease in remission: a prospective cohort study. *Dig Dis*. 2025;43:466-475. <https://doi.org/10.1159/000546486>
 105. Chicco F, Magrì S, Cingolani A, et al. Multidimensional impact of Mediterranean diet on IBD patients. *Inflamm Bowel Dis*. 2021;27:1-9. <https://doi.org/10.1093/ibd/izaa097>
 106. García-Mateo S, Martínez-Domínguez SJ, Gargallo-Puyuelo CJ, et al. Healthy lifestyle is a protective factor from moderate and severe relapses and steroid use in inflammatory bowel disease: a prospective cohort study. *Inflamm Bowel Dis*. 2025;31:95-104. <https://doi.org/10.1093/ibd/izae062>
 107. Peng Z, Yi J, Liu X. A low-FODMAP diet provides benefits for functional gastrointestinal symptoms but not for improving stool consistency and mucosal inflammation in IBD: a systematic review and meta-analysis. *Nutrients*. 2022;14:2072. <https://doi.org/10.3390/nu14102072>
 108. Cox SR, Lindsay JO, Fromentin S, et al. Effects of Low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial. *Gastroenterology*. 2020;158:176-188. e7. <https://doi.org/10.1053/j.gastro.2019.09.024>
 109. Greveson K, Shepherd T, Mulligan JP, et al. Travel health and pre-travel preparation in the patient with inflammatory bowel disease. *Frontline Gastroenterol*. 2016;7:60-65. <https://doi.org/10.1136/flgastro-2014-100548>
 110. Philip V, Soubieries A, Poullis A. Health concerns associated with travelling with inflammatory bowel disease (IBD): a questionnaire survey. *Clin Med (Lond)*. 2018;18:288-292. <https://doi.org/10.7861/clinmedicine.18-4-288>
 111. Aluzaita K, Greveson K, Ben-Horin S, Leong R, Haj O, Schultz M. Barriers to international travel in inflammatory bowel disease patients. *J Travel Med*. 2021;28:taaa197. <https://doi.org/10.1093/jtm/taaa197>
 112. Tan EM, Marcelin JR, Virk A. Pre-travel counseling for immunocompromised travelers: a 12-year single-center retrospective review. *Infect Dis Health*. 2019;24:13-22. <https://doi.org/10.1016/j.idh.2018.09.083>
 113. Chan W, Shim HH, Ng SC, et al.; Asia-Pacific Crohn's and Colitis Epidemiologic Study (ACCESS) Study Group. A global survey of gastroenterologists' travel advice to patients with inflammatory bowel disease on immunosuppressive agents and management of those visiting tuberculosis-endemic areas. *J Crohns Colitis*. 2018;12:1261-1269. <https://doi.org/10.1093/ecco-jcc/jjy110>
 114. Reich J, Wasan S, Farraye FA. Vaccinating patients with inflammatory bowel disease. *Gastroenterol Hepatol (N Y)*. 2016;12:540-546.
 115. Kim AH, Girgis A, De Cruz P, et al. Development and feasibility of a web-based decision aid for patients with ulcerative colitis: qualitative pilot study. *J Med Internet Res*. 2021;23:e15946. <https://doi.org/10.2196/15946>
 116. Baker DM, Marshall JH, Lee MJ, Jones GL, Brown SR, Lobo AJ. A systematic review of internet decision-making resources for patients considering surgery for ulcerative colitis. *Inflamm Bowel Dis*. 2017;23:1293-1300. <https://doi.org/10.1097/MIB.0000000000001198>
 117. Lee MJ, Jones GL, Lobo AJ, Brown SR, p CDC. Survey to define informational needs of patients undergoing surgery for Crohn's anal fistula. *Colorectal Dis*. 2021;23:132-144. <https://doi.org/10.1111/codi.15423>
 118. Gordon M, Sinopoulou V, Ibrahim U, Abdulshafea M, Bracewell K, Akobeng AK. Patient education interventions for the management of inflammatory bowel disease. *Cochrane Database Syst Rev*. 2023;5:CD013854. <https://doi.org/10.1002/14651858.CD013854.pub2>
 119. Alsafi Z, Snell A, Segal JP. Prevalence of 'pouch failure' of the ileoanal pouch in ulcerative colitis: a systematic review and meta-analysis. *Int J Colorectal Dis*. 2022;37:357-364. <https://doi.org/10.1007/s00384-021-04067-6>
 120. Chen SY, Radomski SN, Stem M, et al. National trends and outcomes of total proctocolectomy and completion proctectomy ileal pouch-anal anastomosis procedures for ulcerative colitis. *Colorectal Dis*. 2024;26:497-507. <https://doi.org/10.1111/codi.16891>
 121. McKenna NP, Mathis KL, Khasawneh MA, et al. Obese patients undergoing ileal pouch-anal anastomosis: short-and long-term surgical outcomes. *Inflamm Bowel Dis*. 2017;23:2142-2146. <https://doi.org/10.1097/MIB.0000000000001238>
 122. Leeds IL, Holubar SD, Hull TL, et al. Short- and long-term outcomes of ileal pouch anal anastomosis construction in obese patients with ulcerative colitis. *Dis Colon Rectum*. 2022;65:e782-e9. <https://doi.org/10.1097/DCR.0000000000002169>
 123. Hicks G, Abdulaal A, Slesser AAP, Mohsen Y. Outcomes of inflammatory bowel disease surgery in obese versus non-obese patients: a meta-analysis. *Tech Coloproctol*. 2019;23:947-955. <https://doi.org/10.1007/s10151-019-02080-0>
 124. Egberg MD, Galanko JA, Banegas M, et al. Obesity increases the risk of hospital readmission following intestinal surgery for children with Crohn disease. *J Pediatr Gastroenterol Nutr*. 2021;73:620-625. <https://doi.org/10.1097/MPG.0000000000003251>
 125. Fiorindi C, Cuffaro F, Piemonte G, et al. Effect of long-lasting nutritional prehabilitation on postoperative outcome in elective surgery for IBD. *Clin Nutr*. 2021;40:928-935. <https://doi.org/10.1016/j.clnu.2020.06.020>
 126. Rizzo A, Valenti A, Gianolio S, et al. CASTOMized project: a new comprehensive collaborative approach between case manager and stoma care nurse. *Br J Nurs*. 2025;34:S20-S27. <https://doi.org/10.12968/bjon.2024.0330>
 127. Grahm SW, Lowry AC, Osborne MC, et al. System-wide improvement for transitions after ileostomy surgery: can intensive monitoring of protocol compliance decrease readmissions? A randomized trial. *Dis Colon Rectum*. 2019;62:363-370. <https://doi.org/10.1097/DCR.0000000000001286>
 128. Hasil L, Krug S, Atkins M, Buhler S. Exploring the experiences of patients who receive nutrition education for ostomy care: a qualitative research design. *Nutr Clin Pract*. 2025;40:397-404. <https://doi.org/10.1002/ncp.11257>
 129. Andersen FB, Kjellberg J, Ibsen R, Sternhufvud C, Petersen B. The clinical and economic burden of illness in the first two years after ostomy creation: a nationwide Danish cohort study. *Expert Rev Pharmacoecon Outcomes Res*. 2024;24:567-575. <https://doi.org/10.1080/14737167.2024.2324047>
 130. D'Ambrosio F, Pappalardo C, Scardigno A, Maida A, Ricciardi R, Calabrò GE. Peristomal skin complications in ileostomy and colostomy patients: what we need to know from a public health perspective. *Int J Environ Res Public Health*. 2022;20:79. <https://doi.org/10.3390/ijerph20010079>

131. David JG, Dotson J, Mackner L; ImproveCareNow Learning Health System. ImproveCareNow Learning Health S. Is it "all in the bag?" Multidisciplinary perspectives on ostomy surgery in pediatric IBD across the ImproveCareNow network. *JPGN Rep.* 2024;5:101-109. <https://doi.org/10.1002/jpr3.12044>
132. David JG, Dotson JL, Mackner L. Multidisciplinary perspectives on medical decision-making for ostomy surgery in pediatric IBD: themes from focus groups. *J Clin Psychol Med Settings.* 2025;32:278-285. <https://doi.org/10.1007/s10880-024-10036-2>
133. Bouwknegt DG, van der Weide AHC, Dijkstra G, et al. Pregnancy with a stoma is feasible, though associated with manageable complications. *Inflamm Bowel Dis.* 2025;31:2195-2203. <https://doi.org/10.1093/ibd/izae301>
134. Dukleska K, Berman L, Aka AA, Vinocur CD, Teeple EA. Short-term outcomes in children undergoing restorative proctocolectomy with ileal-pouch anal anastomosis. *J Pediatr Surg.* 2018;53:1154-1159. <https://doi.org/10.1016/j.jpedsurg.2018.02.075>
135. Abdalkodous M, Franklyn J, Balasubramanya S, et al. Long-term mental and physical quality of life outcomes following ileal pouch anal anastomosis surgery. *Ann R Coll Surg Engl.* 2025;107:18-24. <https://doi.org/10.1308/rcsann.2023.0075>
136. Sceats LA, Dehghan MS, Rumer KK, Trickey A, Morris AM, Kin C. Surgery, stomas, and anxiety and depression in inflammatory bowel disease: a retrospective cohort analysis of privately insured patients. *Colorectal Dis.* 2020;22:544-553. <https://doi.org/10.1111/codi.14905>
137. Garcia Garcia L, Emile SH, Linkeshwaran L, Wignakumar A, Wexner SD. A literature review on the role of artificial intelligence-based chatbots in patient education in colorectal surgery. *Surgery.* 2025;183:109393. <https://doi.org/10.1016/j.surg.2025.109393>
138. Alves Martins BA, Villar MT, Ferreira LVG, Ramos de Carvalho B, Avellaneda N, de Sousa JB. Long-term complications of proctectomy for refractory perianal Crohn's disease: a narrative review. *J Clin Med.* 2025;14:2802. <https://doi.org/10.3390/jcm14082802>
139. Celentano V, Rafique H, Jerome M, et al. Development of a specialist ileoanal pouch surgery pathway: a multidisciplinary patient-centred approach. *Frontline Gastroenterol.* 2023;14:244-248. <https://doi.org/10.1136/flgastro-2022-102267>
140. Lightner AL, Dattani S, Dozois EJ, Moncrief SB, Pemberton JH, Mathis KL. Pouch excision: indications and outcomes. *Colorectal Dis.* 2017;19:912-916. <https://doi.org/10.1111/codi.13673>
141. Bunce JA, Lund JN, Tierney GM. Urgency adjusted outcomes of emergency abdominal surgery for inflammatory bowel disease. *World J Surg.* 2024;48:1883-1891. <https://doi.org/10.1002/wjvs.12257>
142. Angistriotis A, Shen B, Kiran RP. Construction of and conversion to continent ileostomy: a systematic review. *Dis Colon Rectum.* 2022;65:S26-S36. <https://doi.org/10.1097/DCR.0000000000002631>
143. Gordon H, Burisch J, Ellul P, et al. ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease. *J Crohns Colitis.* 2024;18:1-37. <https://doi.org/10.1093/ecco-jcc/fjad108>
144. Greveson K, Haj O, Hart A, Geransar P, Zmora O. Management of perianal fistulas associated with Crohn disease: a nurse's perspective. *Gastroenterol Nurs.* 2024;47:428-446. <https://doi.org/10.1097/SGA.0000000000000833>
145. Adegbola SO, Dibley L, Sahnun K, et al. Burden of disease and adaptation to life in patients with Crohn's perianal fistula: a qualitative exploration. *Health Qual Life Outcomes.* 2020;18:370. <https://doi.org/10.1186/s12955-020-01622-7>
146. Lee JL, Yoon YS, Yu CS. Treatment strategy for perianal fistulas in Crohn disease patients: the surgeon's point of view. *Ann Coloproctol.* 2021;37:5-15. <https://doi.org/10.3393/ac.2021.02.08>
147. Garrick V, Stenhouse E, Haddock G, Russell RK. A multidisciplinary team model of caring for patients with perianal Crohn's disease incorporating a literature review, topical therapy and personal practice. *Frontline Gastroenterol.* 2013;4:152-160. <https://doi.org/10.1136/flgastro-2012-100160>
148. Blunck D, Kastner L, Nissen M, Winkler J. The effectiveness of patient training in inflammatory bowel disease knowledge via Instagram: randomized controlled trial. *J Med Internet Res.* 2022;24:e36767. <https://doi.org/10.2196/36767>
149. Vuyuru SK, Ma C, Sharma T, et al. Characteristics of interventional trials for patients living with intestinal stoma registered in clinicaltrials.gov with a focus on inflammatory bowel disease. *Inflamm Bowel Dis.* 2024;30:2037-2045. <https://doi.org/10.1093/ibd/izad293>
150. Plechschmidt J, Fietkau K, Hepp T, et al. Clinical pharmacist counselling improves long-term medication safety and patient-reported outcomes in anti-TNF-treated patients with inflammatory bowel diseases: the prospective, randomized AdPhaNced Trial. *Inflamm Bowel Dis.* 2025;31:77-86. <https://doi.org/10.1093/ibd/izae040>
151. Norouzkhani N, Faramarzi M, Ghodousi Moghadam S, et al. Identification of the informational and supportive needs of patients diagnosed with inflammatory bowel disease: a scoping review. *Front Psychol.* 2023;14:1055449. <https://doi.org/10.3389/fpsyg.2023.1055449>
152. Spinelli A, Yanai H, Girardi P, et al. The impact of Crohn's perianal fistula on quality of life: results of an international patient survey. *Crohns Colitis 360.* 2023;5:otad036. <https://doi.org/10.1093/crocol/otad036>
153. Pakpoor J, Travis S. Why studying urgency is urgent. *Gastroenterol Hepatol (N Y).* 2023;19:95-100.
154. Blackett JW, Bharucha AE. Fecal incontinence in adults: new therapies. *Am J Gastroenterol.* 2025;120:2027-2041. <https://doi.org/10.14309/ajg.0000000000003413>
155. Norton C, Syred J, Kerry S, et al. Supported online self-management versus care as usual for symptoms of fatigue, pain and urgency/incontinence in adults with inflammatory bowel disease (IBD-BOOST): study protocol for a randomised controlled trial. *Trials.* 2021;22:516. <https://doi.org/10.1186/s13063-021-05466-4>
156. Moss-Morris R, Norton C, Hart A, et al. Digital cognitive behavioural self-management programme for fatigue, pain, and faecal incontinence in inflammatory bowel disease (IBD-BOOST): a multicentre, parallel, randomised controlled trial. *Lancet Digit Health.* 2025;7:100906. <https://doi.org/10.1016/j.landig.2025.100906>
157. Dibley L, Hart A, Duncan J, et al. Supported intervention versus intervention alone for management of fecal incontinence in patients with inflammatory bowel disease: a multicenter mixed-methods randomized controlled trial. *J Wound Ostomy Continence Nurs.* 2023;50:235-244. <https://doi.org/10.1097/WON.0000000000000979>
158. Khera AJ, Chase JW, Salzberg M, Thompson AJV, Kamm MA. Gut-directed pelvic floor behavioral treatment for fecal incontinence and constipation in patients with inflammatory bowel disease. *Inflamm Bowel Dis.* 2019;25:620-626. <https://doi.org/10.1093/ibd/izy344>
159. Wileman V, Chilcot J, Norton C, et al. Modifiable psychological factors are associated with clusters of pain, fatigue, fecal incontinence, and irritable bowel syndrome-type symptoms in inflammatory bowel disease: a latent profile analysis. *J Crohns Colitis.* 2025;19:jjae183.
160. Coates MD, Clarke K, Williams E, et al. Abdominal pain in inflammatory bowel disease: an evidence-based, multidisciplinary review.

- Crohn's Colitis* 360. 2023;5:otad055. <https://doi.org/10.1093/crocol/otad055>
161. Ryrso C, Fransgard T, Andersen LPK. Pain, opioid consumption, and epidural anesthesia in patients with inflammatory bowel disease undergoing laparoscopic subtotal colectomy: an observational cohort study. *Tech Coloproctol.* 2025;29:75. <https://doi.org/10.1007/s10151-025-03118-2>
 162. Odes S, Friger M, Sergienko R, et al. Simple pain measures reveal psycho-social pathology in patients with Crohn's disease. *World J Gastroenterol.* 2017;23:1076-1089. <https://doi.org/10.3748/wjg.v23.i6.1076>
 163. Sweeney L, Windgassen S, Artom M, Norton C, Fawson S, Moss-Morris R. A novel digital self-management intervention for symptoms of fatigue, pain, and urgency in inflammatory bowel disease: describing the process of development. *JMIR Form Res.* 2022;6:e33001. <https://doi.org/10.2196/33001>
 164. Rajai N, Abbasi Z, Pishgooe AH, Teymouri F, Imanipour M. Effects of self-acupressure on quality of life and abdominal pain severity among patients with inflammatory bowel disease: a randomized sham-controlled trial. *J Ayurveda Integr Med.* 2025;16:101080. <https://doi.org/10.1016/j.jaim.2024.101080>
 165. Abdul Khadar TF, Ramalingam V. Effectiveness of the specific mobility exercises on pain intensity and quality of life among stoma patients: a quasi-experimental study. *Cureus.* 2024;16:e63715. <https://doi.org/10.7759/cureus.63715>
 166. Fawson S, Dibley L, Smith K, et al. Developing an online program for self-management of fatigue, pain, and urgency in inflammatory bowel disease: patients' needs and wants. *Dig Dis Sci.* 2022;67:2813-2826. <https://doi.org/10.1007/s10620-021-07109-9>
 167. Sweeney L, Moss-Morris R, Czuber-Dochan W, Norton C. Pain management in inflammatory bowel disease: feasibility of an online therapist-supported CBT-based self-management intervention. *Pilot Feasibility Stud.* 2021;7:95. <https://doi.org/10.1186/s40814-021-00829-9>
 168. Vegni E, Gilardi D, Bonovas S, et al. Illness perception in inflammatory bowel disease patients is different between patients with active disease or in remission: a prospective cohort study. *J Crohn's Colitis.* 2019;13:417-423. <https://doi.org/10.1093/ecco-jcc/jjy183>
 169. Roukas C, Miller L, Cléirigh Büttner F, et al. P1277. Cost-effectiveness of BOOST online intervention for supported self-management of pain, fatigue and bowel incontinence in inflammatory bowel disease. *Journal of Crohn's & Colitis.* 2025;19:i2305-i2306. <https://doi.org/10.1093/ecco-jcc/jjae190.1451>
 170. Opheim R, Moum B, Grimstad BT, et al. Self-esteem in patients with inflammatory bowel disease. *Qual Life Res.* 2020;29:1839-1846. <https://doi.org/10.1007/s11136-020-02467-9>
 171. Czuber-Dochan W, Ream E, Norton C. Review article: description and management of fatigue in inflammatory bowel disease. *Aliment Pharmacol Ther.* 2013;37:505-516. <https://doi.org/10.1111/apt.12205>
 172. D'Silva A, Fox DE, Nasser Y, et al. Prevalence and risk factors for fatigue in adults with inflammatory bowel disease: a systematic review with meta-analysis. *Clin Gastroenterol Hepatol.* 2022;20:995-1009 e7. <https://doi.org/10.1016/j.cgh.2021.06.034>
 173. Artom M, Czuber-Dochan W, Sturt J, Proudfoot H, Roberts D, Norton C. Cognitive-behavioural therapy for the management of inflammatory bowel disease-fatigue: a feasibility randomised controlled trial. *Pilot Feasibility Stud.* 2019;5:145. <https://doi.org/10.1186/s40814-019-0538-y>
 174. O'Connor A, Ratnakumaran R, Warren L, et al. Randomized controlled trial: a pilot study of a psychoeducational intervention for fatigue in patients with quiescent inflammatory bowel disease. *Ther Adv Chronic Dis.* 2019;10:2040622319838439.
 175. Farrell D, Artom M, Czuber-Dochan W, Jelsness-Jørgensen LP, Norton C, Savage E. Interventions for fatigue in inflammatory bowel disease. *Cochrane Database Syst Rev.* 2020;4:CD012005. <https://doi.org/10.1002/14651858.CD012005.pub2>
 176. Davis SP, Bolin LP, Crane PB, Wei H, Crandell J. Non-pharmacological interventions to manage fatigue in adults with inflammatory bowel disease: a systematic review and meta-analysis. *Complement Ther Clin Pract.* 2020;41:101229. <https://doi.org/10.1016/j.ctcp.2020.101229>
 177. Horta D, Lira A, Sanchez-Lloansi M, et al. A prospective pilot randomized study: electroacupuncture vs. sham procedure for the treatment of fatigue in patients with quiescent inflammatory bowel disease. *Inflamm Bowel Dis.* 2020;26:484-492.
 178. Huang C, Czuber-Dochan W, Norton C. Home-based transcutaneous electrical acupuncture-point stimulation for depressive symptoms in inflammatory bowel disease: a randomized feasibility study. *Eur J Gastroenterol Hepatol.* 2025;37:1326-1336. <https://doi.org/10.1097/MEG.0000000000003034>
 179. Emerson C, Barhoun P, Olive L, et al. A systematic review of psychological treatments to manage fatigue in patients with inflammatory bowel disease. *J Psychosom Res.* 2021;147:110524. <https://doi.org/10.1016/j.jpsychores.2021.110524>
 180. You L, Guo N, Wang T, et al. Effects of aromatherapy on fatigue, quality of sleep and quality of life in patients with inflammatory bowel disease: a feasibility study. *Complement Ther Clin Pract.* 2022;49:101648. <https://doi.org/10.1016/j.ctcp.2022.101648>
 181. Bredero QM, Fleer J, Smink A, et al. Long-term treatment outcomes of mindfulness-based cognitive therapy for fatigue in patients with inflammatory bowel disease: results of a randomized controlled trial. *J Psychosom Res.* 2024;187:111949. <https://doi.org/10.1016/j.jpsychores.2024.111949>
 182. Bredero QM, Fleer J, Smink A, et al. Mindfulness-based cognitive therapy for fatigue in patients with inflammatory bowel disease: results of a randomized controlled trial. *Mindfulness (N Y).* 2023;14:19-32. <https://doi.org/10.1007/s12671-022-02057-5>
 183. Czuber-Dochan W, Norton C, Bassett P, et al. Development and psychometric testing of inflammatory bowel disease fatigue (IBD-F) patient self-assessment scale. *J Crohn's Colitis.* 2014;8:1398-1406. <https://doi.org/10.1016/j.crohns.2014.04.013>
 184. Lee YJ, Kwon EJ, Park DI, Park SH, Hwang SW, Ye BD. Effectiveness of an app-based walking program for obese patients with inflammatory bowel disease in Korea: a single-blind parallel-group randomized clinical trial. *BMC Gastroenterol.* 2025;25:417. <https://doi.org/10.1186/s12876-025-03962-4>
 185. Loveikyte R, Koppelman LJM, Blijleven MJH, et al. Multimodal lifestyle intervention improves fatigue in quiescent inflammatory bowel disease: a controlled study. *Crohn's Colitis* 360. 2025;7:otaf009. <https://doi.org/10.1093/crocol/otaf009>
 186. McNelly AS, Monti M, Grimble GK, et al. The effect of increasing physical activity and/or omega-3 supplementation on fatigue in inflammatory bowel disease. *Gastrointestinal Nursing.* 2016;14:39-50. <https://doi.org/10.12968/gasn.2016.14.8.39>
 187. Radford SJ, McGing J, Czuber-Dochan W, Moran G. Systematic review: the impact of inflammatory bowel disease-related fatigue on health-related quality of life. *Frontline Gastroenterol.* 2021;12:11-21. <https://doi.org/10.1136/flgastro-2019-101355>
 188. Goren G, Schwartz D, Friger M, et al. Randomized controlled trial of cognitive-behavioral and mindfulness-based stress reduction on the quality of life of patients with Crohn disease. *Inflamm Bowel Dis.* 2022;28:393-408. <https://doi.org/10.1093/ibd/izab083>

189. Regev S, Schwartz D, Sarid O, et al. Randomised clinical trial: psychological intervention improves work productivity and daily activity by reducing abdominal pain and fatigue in Crohn's disease. *Aliment Pharmacol Ther.* 2023;57:861-871. <https://doi.org/10.1111/apt.17399>
190. Bager P, Hvas CL, Rud CL, Dahlerup JF. Randomised clinical trial: high-dose oral thiamine versus placebo for chronic fatigue in patients with quiescent inflammatory bowel disease. *Aliment Pharmacol Ther.* 2021;53:79-86. <https://doi.org/10.1111/apt.16166>
191. Bager P, Hvas CL, Rud CL, Dahlerup JF. Long-term maintenance treatment with 300 mg thiamine for fatigue in patients with inflammatory bowel disease: results from an open-label extension of the TARIF study. *Scand J Gastroenterol.* 2022;57:37-43. <https://doi.org/10.1080/00365521.2021.1983640>
192. Bager P, Hvas CL, Hansen MM, Ueland P, Dahlerup JF. B-vitamins, related vitamins, and metabolites in patients with quiescent inflammatory bowel disease and chronic fatigue treated with high dose oral thiamine. *Mol Med.* 2023;29:143. <https://doi.org/10.1186/s10020-023-00741-3>
193. Bermúdez-Sánchez S, Bager P, Dahlerup JF, et al. Thiamine-reduced fatigue in quiescent inflammatory bowel disease is linked to faecalibacterium prausnitzii abundance. *Gastro Hep Adv.* 2025;4:100533. <https://doi.org/10.1016/j.gastha.2024.08.012>
194. Purewal S, Chapman S, Czuber-Dochan W, Selinger C, Steed H, Brookes MJ. Systematic review: the consequences of psychosocial effects of inflammatory bowel disease on patients' reproductive health. *Aliment Pharmacol Ther.* 2018;48:1202-1212. <https://doi.org/10.1111/apt.15019>
195. Lehmann V, Bastiaens D, Bosch J, Bennebroek Evertsz F. Sexual functioning in patients with inflammatory bowel diseases (IBD): prevalence, predictors, and potential benefits of cognitive behavioral therapy (CBT). *Scand J Gastroenterol.* 2025;60:707-715. <https://doi.org/10.1080/00365521.2025.2506141>
196. Romano L, Fonticelli M, Miranda A, et al. Sexual dysfunctions in inflammatory bowel disease: role of Mediterranean diet and quality of life. *Andrology.* 2025;13:1693-1701. <https://doi.org/10.1111/andr.13791>
197. Mills K, Gala K, Croghan I, et al. Evaluating the need and impact of a multifaceted wellness program on the health-related quality of life (HRQOL) in female patients with inflammatory bowel disease. *Am J Gastroenterol.* 2024;119:S984-S985. <https://doi.org/10.14309/01.ajg.0001034876.07597.c2>
198. Nielsen OH, Gubatan JM, Kolho KL, Streett SE, Maxwell C. Updates on the management of inflammatory bowel disease from periconception to pregnancy and lactation. *Lancet.* 2024;403:1291-1303. [https://doi.org/10.1016/S0140-6736\(24\)00052-7](https://doi.org/10.1016/S0140-6736(24)00052-7)
199. Sousa P, Gisbert JP, Julsgaard M, Selinger CP, Chaparro M. Navigating reproductive care in patients with inflammatory bowel disease: a comprehensive review. *J Crohns Colitis.* 2024;18:ii16-ii30. <https://doi.org/10.1093/ecco-jcc/ijae048>
200. Armuzzi A, Bortoli A, Castiglione F, et al. Female reproductive health and inflammatory bowel disease: a practice-based review. *Dig Liver Dis.* 2022;54:19-29. <https://doi.org/10.1016/j.dld.2021.05.020>
201. Hacker KS, Bedell A. Reproductive and sexual health concerns in gastrointestinal illness: a narrative review. *Transl Gastroenterol Hepatol.* 2025;10:15. <https://doi.org/10.21037/tgh-24-38>
202. De Dycker E, Lenie S, Ceulemans M, et al. The development of a multidisciplinary care pathway for patients with inflammatory bowel disease before, during and after pregnancy. *J Clin Med.* 2025;14:2644. <https://doi.org/10.3390/jcm14082644>
203. Lee YJ, Kim HW, Kim YH, Yang SK, Kim JY. Effects of a pre-conception care program in women with inflammatory bowel disease: a mixed-methods study including a randomized controlled trial. *J Korean Acad Nurs.* 2024;54:386-402. <https://doi.org/10.4040/jkan.24010>
204. Liu E, Chatten K, Limdi JK. Conception, pregnancy and inflammatory bowel disease—Current concepts for the practising clinician. *Indian J Gastroenterol.* 2026;45:152-164. <https://doi.org/10.1007/s12664-024-01563-9>
205. Druvefors E, Myrelid P, Andersson RE, Landerholm K. Female and male fertility after colectomy and reconstructive surgery in inflammatory bowel disease: a national cohort study from Sweden. *J Crohns Colitis.* 2023;17:1631-1638. <https://doi.org/10.1093/ecco-jcc/ijad079>
206. Laube R, Liu E, Li Y, Leong RW, Limdi J, Selinger C. Gastroenterology team members' knowledge and practices with fertility therapy for women with inflammatory bowel disease. *Ther Adv Gastroenterol.* 2022;15:17562848221087543. <https://doi.org/10.1177/17562848221087543>
207. Selinger C, Carey N, Cassere S, et al. Standards for the provision of antenatal care for patients with inflammatory bowel disease: guidance endorsed by the British Society of Gastroenterology and the British Maternal and Fetal Medicine Society. *Frontline Gastroenterol.* 2021;12:182-187. <https://doi.org/10.1136/flgastro-2020-101459>
208. Li RX, Wu T, Li XF, et al. Inadequate pregnancy-specific knowledge among patients with inflammatory bowel disease: a multicenter survey in China. *J Dig Dis.* 2024;25:100-108. <https://doi.org/10.1111/1751-2980.13258>
209. Boyd T, Friedman S. Challenges and opportunities for advancing research and improving care for sexual and gender minorities with inflammatory bowel disease. *Inflamm Bowel Dis.* 2023;29:672-674. <https://doi.org/10.1093/ibd/izac229>
210. Newman KL, Chedid VG, Boden EK. A systematic review of inflammatory bowel disease epidemiology and health outcomes in sexual and gender minority individuals. *Clin Gastroenterol Hepatol.* 2023;21:1127-1133. <https://doi.org/10.1016/j.cgh.2023.02.006>
211. Kamp K, Yang P-L, Tsai C-S, et al. Gender and sex differences in abdominal pain, fatigue, and psychological symptoms among adults with inflammatory bowel disease: a network analysis. *Inflamm Bowel Dis.* 2025;31:442-449. <https://doi.org/10.1093/ibd/izae279>
212. Newman KL, Wren PA, Long MD, Higgins PDR. Health outcomes, discrimination, and stigma among sexual and gender minority people with inflammatory bowel disease. *Inflamm Bowel Dis.* 2025;31:2429-2437. <https://doi.org/10.1093/ibd/izaf054>
213. Colwill M, Pollok R, Seal L, Poullis A. Impact of gender identity in the inflammatory bowel disease population: an evidence review and practical steps for gastroenterologists. *Frontline Gastroenterol.* 2024;15:401-407. <https://doi.org/10.1136/flgastro-2024-102658>
214. Cox SR, Czuber-Dochan W, Wall CL, et al. Improving food-related quality of life in inflammatory bowel disease through a novel web resource: a feasibility randomised controlled trial. *Nutrients.* 2022;14:4292. <https://doi.org/10.3390/nu14204292>
215. Jaghult S, Larson J, Wredling R, Kapraali M. A multiprofessional education programme for patients with inflammatory bowel disease: a randomized controlled trial. *Scand J Gastroenterol.* 2007;42:1452-1459. <https://doi.org/10.1080/00365520701439685>
216. Kamat N, Rajan Mallayasamy S, Sharma P, Kamath A, Pai CG. Video assisted patient education improves compliance with follow up and depression scores in Inflammatory Bowel Diseases. *Postgrad Med.* 2018;130:355-360. <https://doi.org/10.1080/00325481.2018.1442978>

217. Haapamaki J, Heikkinen E, Sipponen T, Roine RP, Arkkila P. The impact of an adaptation course on health-related quality of life and functional capacity of patients with inflammatory bowel disease. *Scand J Gastroenterol*. 2018;53:1074-1078. <https://doi.org/10.1080/00365521.2018.1500639>
218. Oxelmark L, Magnusson A, Lofberg R, Hilleras P. Group-based intervention program in inflammatory bowel disease patients: effects on quality of life. *Inflamm Bowel Dis*. 2007;13:182-190. <https://doi.org/10.1002/ibd.20061>
219. Moreau J, Hammoudi N, Marthey L, et al. GETAID. Impact of an education programme on IBD patients' skills: results of a Randomised Controlled Multicentre Study [ECIPE]. *J Crohns Colitis*. 2021;15:432-440. <https://doi.org/10.1093/ecco-jcc/jjaa195>
220. Navarro-Correal E, Ibarz A, Basagaña-Farres M, Feijoo-Cid M, Espart A, Selva L. Educational interventions for newly diagnosed patients with inflammatory bowel disease: a scoping review. *Gastroenterol Nurs*. 2023;46:30-40. <https://doi.org/10.1097/SGA.0000000000000688>
221. Gasparetto M, Narula P, Wong C, et al. Efficacy of digital health technologies in the management of inflammatory bowel disease: an umbrella review. *Lancet Digit Health*. 2025;7:100843. <https://doi.org/10.1016/j.landig.2024.12.007>
222. Pang L, Liu H, Liu Z, et al. Role of telemedicine in inflammatory bowel disease: systematic review and meta-analysis of randomized controlled trials. *J Med Internet Res*. 2022;24:e28978. <https://doi.org/10.2196/28978>
223. Gordon M, Sinopoulou V, Lakunina S, Gjuladin-Hellon T, Bracewell K, Akobeng AK. Remote care through telehealth for people with inflammatory bowel disease. *Cochrane Database Syst Rev*. 2023;5:CD014821. <https://doi.org/10.1002/14651858.CD014821.pub2>
224. Kuriakose Kuzhiyanjal AJ, Nigam GB, Antoniou GA, Farraye FA, Cross RK, Limdi JK. Management of inflammatory bowel disease using e-health technologies: a systematic review and meta-analysis. *J Crohns Colitis*. 2023;17:1596-1613. <https://doi.org/10.1093/ecco-jcc/jjad075>
225. Huang VW, Reich KM, Fedorak RN. Distance management of inflammatory bowel disease: systematic review and meta-analysis. *World J Gastroenterol*. 2014;20:829-842. <https://doi.org/10.3748/wjg.v20.i3.829>
226. Rohde JA, Barker JO, Noar SM. Impact of eHealth technologies on patient outcomes: a meta-analysis of chronic gastrointestinal illness interventions. *Transl Behav Med*. 2021;11:1-10. <https://doi.org/10.1093/tbm/ibz166>
227. Gohil S, Majd Z, Sheneman JC, Abughosh SM. Interventions to improve medication adherence in inflammatory bowel disease: a systematic review. *Patient Educ Couns*. 2022;105:1731-1742. <https://doi.org/10.1016/j.pec.2021.10.017>
228. Helsel BC, Williams JE, Lawson K, Liang J, Markowitz J. Telemedicine and mobile health technology are effective in the management of digestive diseases: a systematic review. *Dig Dis Sci*. 2018;63:1392-1408. <https://doi.org/10.1007/s10620-018-5054-z>
229. Nguyen NH, Martinez I, Atreja A, et al. Digital health technologies for remote monitoring and management of inflammatory bowel disease: a systematic review. *Am J Gastroenterol*. 2022;117:78-97. <https://doi.org/10.14309/ajg.0000000000001545>
230. Tontini GE, Rimondi A, Vernero M, et al. Artificial intelligence in gastrointestinal endoscopy for inflammatory bowel disease: a systematic review and new horizons. *Ther Adv Gastroenterol*. 2021;14:17562848211017730. <https://doi.org/10.1177/17562848211017730>
231. Sachan A, Kakadiya R, Mishra S, et al. Artificial intelligence for discrimination of Crohn's disease and gastrointestinal tuberculosis: a systematic review. *J Gastroenterol Hepatol*. 2024;39:422-430. <https://doi.org/10.1111/jgh.16430>
232. Kawamoto A, Takenaka K, Okamoto R, Watanabe M, Ohtsuka K. Systematic review of artificial intelligence-based image diagnosis for inflammatory bowel disease. *Dig Endosc*. 2022;34:1311-1319. <https://doi.org/10.1111/den.14334>
233. Akbarian P, Asadi F, Sabahi A. Developing mobile health applications for inflammatory bowel disease: a systematic review of features and technologies. *Middle East J Dig Dis*. 2024;16:211-220. <https://doi.org/10.34172/mejdd.2024.394>
234. Lusetti F, Maimaris S, La Rosa GP, et al. Applications of generative artificial intelligence in inflammatory bowel disease: a systematic review. *Dig Liver Dis*. 2025;57:1883-1889. <https://doi.org/10.1016/j.dld.2025.04.026>
235. Stafford IS, Gosink MM, Mossotto E, Ennis S, Hauben M. A systematic review of artificial intelligence and machine learning applications to inflammatory bowel disease, with practical guidelines for interpretation. *Inflamm Bowel Dis*. 2022;28:1573-1583. <https://doi.org/10.1093/ibd/izac115>
236. Lee MCM, Farahvash A, Zezos P. Artificial intelligence for classification of endoscopic severity of inflammatory bowel disease: a systematic review and critical appraisal. *Inflamm Bowel Dis*. 2025;31:2296-2310. <https://doi.org/10.1093/ibd/izaf050>
237. Ceccato HD, Silva TAdOE, Genaro LM, et al. Artificial intelligence use for precision medicine in inflammatory bowel disease: a systematic review. *Am J Transl Res*. 2025;17:28-46. <https://doi.org/10.62347/XILL3707>
238. Mizuno H, Fujimoto Y, Furukawa Y, et al. Development and validation of an e-learning educational program for acquiring basic knowledge in inflammatory bowel disease nursing. *Inflamm Intest Dis*. 2024;9:125-134. <https://doi.org/10.1159/000539005>
239. Berry, Andrew C., Mestas, Lisa, Duffy, Angela, et al. 615. Assessment of inflammatory bowel disease knowledge across an academic nursing facility. *American J of Gastroenterol*. 2016; 111:S282, S284-S4. <https://doi.org/10.14309/00000434-201610001-00615>
240. Ohue T, Menta M. Effectiveness of mentorship using cognitive behavior therapy to reduce burnout and turnover among nurses: intervention impact on mentees. *Nurs Rep*. 2024;14:1026-1036. <https://doi.org/10.3390/nursrep14020077>